Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System
The grading of gliomas based on histological features has been a subject of debate for several decades. A consensus has not yet been reached because of technical limitations and inter-observer variations. While the traditional grading system has failed to stratify the risk of IDH-mutant astrocytoma,...
Saved in:
| Published in | Laboratory investigation Vol. 102; no. 2; pp. 126 - 133 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | English |
| Published |
New York
Elsevier Inc
01.02.2022
Nature Publishing Group US Nature Publishing Group |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0023-6837 1530-0307 1530-0307 |
| DOI | 10.1038/s41374-021-00667-6 |
Cover
| Abstract | The grading of gliomas based on histological features has been a subject of debate for several decades. A consensus has not yet been reached because of technical limitations and inter-observer variations. While the traditional grading system has failed to stratify the risk of IDH-mutant astrocytoma, canonical histological and proliferative markers may be applicable to the risk stratification of IDH-wild-type astrocytoma. Numerous studies have examined molecular markers in order to obtain more clinically relevant information that will improve the risk stratification of gliomas. The CDKN2A/B homozygous deletion for IDH-mutant astrocytoma and the following three criteria for IDH-wild-type astrocytoma: the concurrent gain of whole chromosome 7 and loss of whole chromosome 10, TERT promoter mutations, and EGFR amplification, were identified as independent molecular markers of the worst clinical outcomes. Therefore, the 2021 World Health Organization (WHO) Classification of Tumors of the Central Nervous System adopted these molecular markers into the revised grading criteria of IDH-mutant and -wild-type astrocytoma, respectively, as a grading system within tumor types. Of note, several recent studies have shown that some low-grade IDH-wild-type astrocytoma lacking both the molecular glioblastoma signature and genetic alterations typical of pediatric-type gliomas may demonstrate a relatively indolent clinical course, suggesting the existence of lower-grade adult IDH-wild-type astrocytoma. In terms of oligodendroglioma, IDH-mutant, and 1p/19q codeleted, consistent makers that predict poor outcomes have not yet been identified, and, thus, the current criteria have remained unchanged. Molecular testing to fulfill the revised WHO criteria is, however, not always available worldwide, and in that case, an integrated diagnosis combining all available complementary information is highly recommended. This review discusses controversial issues surrounding legacy grading systems and newly identified potential genetic markers of adult diffuse gliomas and provides perspectives on future grading systems.
The 5th edition of WHO Classification of Tumors of the Central Nervous System adopted new molecular markers into the revised grading criteria of IDH-mutant and -wild-type astrocytoma, i.e., the CDKN2A/B homozygous deletion for IDH-mutant astrocytoma and the following three criteria for IDH-wild-type astrocytoma: the concurrent gain of whole chromosome 7 and loss of whole chromosome 10, TERT promoter mutations, and EGFR amplification, as independent molecular markers of the highest grade. |
|---|---|
| AbstractList | The grading of gliomas based on histological features has been a subject of debate for several decades. A consensus has not yet been reached because of technical limitations and inter-observer variations. While the traditional grading system has failed to stratify the risk of IDH-mutant astrocytoma, canonical histological and proliferative markers may be applicable to the risk stratification of IDH-wild-type astrocytoma. Numerous studies have examined molecular markers in order to obtain more clinically relevant information that will improve the risk stratification of gliomas. The CDKN2A/B homozygous deletion for IDH-mutant astrocytoma and the following three criteria for IDH-wild-type astrocytoma: the concurrent gain of whole chromosome 7 and loss of whole chromosome 10, TERT promoter mutations, and EGFR amplification, were identified as independent molecular markers of the worst clinical outcomes. Therefore, the 2021 World Health Organization (WHO) Classification of Tumors of the Central Nervous System adopted these molecular markers into the revised grading criteria of IDH-mutant and -wild-type astrocytoma, respectively, as a grading system within tumor types. Of note, several recent studies have shown that some low-grade IDH-wild-type astrocytoma lacking both the molecular glioblastoma signature and genetic alterations typical of pediatric-type gliomas may demonstrate a relatively indolent clinical course, suggesting the existence of lower-grade adult IDH-wild-type astrocytoma. In terms of oligodendroglioma, IDH-mutant, and 1p/19q codeleted, consistent makers that predict poor outcomes have not yet been identified, and, thus, the current criteria have remained unchanged. Molecular testing to fulfill the revised WHO criteria is, however, not always available worldwide, and in that case, an integrated diagnosis combining all available complementary information is highly recommended. This review discusses controversial issues surrounding legacy grading systems and newly identified potential genetic markers of adult diffuse gliomas and provides perspectives on future grading systems.The 5th edition of WHO Classification of Tumors of the Central Nervous System adopted new molecular markers into the revised grading criteria of IDH-mutant and -wild-type astrocytoma, i.e., the CDKN2A/B homozygous deletion for IDH-mutant astrocytoma and the following three criteria for IDH-wild-type astrocytoma: the concurrent gain of whole chromosome 7 and loss of whole chromosome 10, TERT promoter mutations, and EGFR amplification, as independent molecular markers of the highest grade. The grading of gliomas based on histological features has been a subject of debate for several decades. A consensus has not yet been reached because of technical limitations and inter-observer variations. While the traditional grading system has failed to stratify the risk of IDH-mutant astrocytoma, canonical histological and proliferative markers may be applicable to the risk stratification of IDH-wild-type astrocytoma. Numerous studies have examined molecular markers in order to obtain more clinically relevant information that will improve the risk stratification of gliomas. The CDKN2A/B homozygous deletion for IDH-mutant astrocytoma and the following three criteria for IDH-wild-type astrocytoma: the concurrent gain of whole chromosome 7 and loss of whole chromosome 10, TERT promoter mutations, and EGFR amplification, were identified as independent molecular markers of the worst clinical outcomes. Therefore, the 2021 World Health Organization (WHO) Classification of Tumors of the Central Nervous System adopted these molecular markers into the revised grading criteria of IDH-mutant and -wild-type astrocytoma, respectively, as a grading system within tumor types. Of note, several recent studies have shown that some low-grade IDH-wild-type astrocytoma lacking both the molecular glioblastoma signature and genetic alterations typical of pediatric-type gliomas may demonstrate a relatively indolent clinical course, suggesting the existence of lower-grade adult IDH-wild-type astrocytoma. In terms of oligodendroglioma, IDH-mutant, and 1p/19q codeleted, consistent makers that predict poor outcomes have not yet been identified, and, thus, the current criteria have remained unchanged. Molecular testing to fulfill the revised WHO criteria is, however, not always available worldwide, and in that case, an integrated diagnosis combining all available complementary information is highly recommended. This review discusses controversial issues surrounding legacy grading systems and newly identified potential genetic markers of adult diffuse gliomas and provides perspectives on future grading systems. The grading of gliomas based on histological features has been a subject of debate for several decades. A consensus has not yet been reached because of technical limitations and inter-observer variations. While the traditional grading system has failed to stratify the risk of IDH-mutant astrocytoma, canonical histological and proliferative markers may be applicable to the risk stratification of IDH-wild-type astrocytoma. Numerous studies have examined molecular markers in order to obtain more clinically relevant information that will improve the risk stratification of gliomas. The CDKN2A/B homozygous deletion for IDH-mutant astrocytoma and the following three criteria for IDH-wild-type astrocytoma: the concurrent gain of whole chromosome 7 and loss of whole chromosome 10, TERT promoter mutations, and EGFR amplification, were identified as independent molecular markers of the worst clinical outcomes. Therefore, the 2021 World Health Organization (WHO) Classification of Tumors of the Central Nervous System adopted these molecular markers into the revised grading criteria of IDH-mutant and -wild-type astrocytoma, respectively, as a grading system within tumor types. Of note, several recent studies have shown that some low-grade IDH-wild-type astrocytoma lacking both the molecular glioblastoma signature and genetic alterations typical of pediatric-type gliomas may demonstrate a relatively indolent clinical course, suggesting the existence of lower-grade adult IDH-wild-type astrocytoma. In terms of oligodendroglioma, IDH-mutant, and 1p/19q codeleted, consistent makers that predict poor outcomes have not yet been identified, and, thus, the current criteria have remained unchanged. Molecular testing to fulfill the revised WHO criteria is, however, not always available worldwide, and in that case, an integrated diagnosis combining all available complementary information is highly recommended. This review discusses controversial issues surrounding legacy grading systems and newly identified potential genetic markers of adult diffuse gliomas and provides perspectives on future grading systems. The 5th edition of WHO Classification of Tumors of the Central Nervous System adopted new molecular markers into the revised grading criteria of IDH-mutant and -wild-type astrocytoma, i.e., the CDKN2A/B homozygous deletion for IDH-mutant astrocytoma and the following three criteria for IDH-wild-type astrocytoma: the concurrent gain of whole chromosome 7 and loss of whole chromosome 10, TERT promoter mutations, and EGFR amplification, as independent molecular markers of the highest grade. The grading of gliomas based on histological features has been a subject of debate for several decades. A consensus has not yet been reached because of technical limitations and inter-observer variations. While the traditional grading system has failed to stratify the risk of IDH-mutant astrocytoma, canonical histological and proliferative markers may be applicable to the risk stratification of IDH-wild-type astrocytoma. Numerous studies have examined molecular markers in order to obtain more clinically relevant information that will improve the risk stratification of gliomas. The CDKN2A/B homozygous deletion for IDH-mutant astrocytoma and the following three criteria for IDH-wild-type astrocytoma: the concurrent gain of whole chromosome 7 and loss of whole chromosome 10, TERT promoter mutations, and EGFR amplification, were identified as independent molecular markers of the worst clinical outcomes. Therefore, the 2021 World Health Organization (WHO) Classification of Tumors of the Central Nervous System adopted these molecular markers into the revised grading criteria of IDH-mutant and -wild-type astrocytoma, respectively, as a grading system within tumor types. Of note, several recent studies have shown that some low-grade IDH-wild-type astrocytoma lacking both the molecular glioblastoma signature and genetic alterations typical of pediatric-type gliomas may demonstrate a relatively indolent clinical course, suggesting the existence of lower-grade adult IDH-wild-type astrocytoma. In terms of oligodendroglioma, IDH-mutant, and 1p/19q codeleted, consistent makers that predict poor outcomes have not yet been identified, and, thus, the current criteria have remained unchanged. Molecular testing to fulfill the revised WHO criteria is, however, not always available worldwide, and in that case, an integrated diagnosis combining all available complementary information is highly recommended. This review discusses controversial issues surrounding legacy grading systems and newly identified potential genetic markers of adult diffuse gliomas and provides perspectives on future grading systems. The 5th edition of WHO Classification of Tumors of the Central Nervous System adopted new molecular markers into the revised grading criteria of IDH-mutant and -wild-type astrocytoma, i.e., the CDKN2A/B homozygous deletion for IDH-mutant astrocytoma and the following three criteria for IDH-wild-type astrocytoma: the concurrent gain of whole chromosome 7 and loss of whole chromosome 10, TERT promoter mutations, and EGFR amplification, as independent molecular markers of the highest grade. The grading of gliomas based on histological features has been a subject of debate for several decades. A consensus has not yet been reached because of technical limitations and inter-observer variations. While the traditional grading system has failed to stratify the risk of IDH-mutant astrocytoma, canonical histological and proliferative markers may be applicable to the risk stratification of IDH-wild-type astrocytoma. Numerous studies have examined molecular markers in order to obtain more clinically relevant information that will improve the risk stratification of gliomas. The CDKN2A/B homozygous deletion for IDH-mutant astrocytoma and the following three criteria for IDH-wild-type astrocytoma: the concurrent gain of whole chromosome 7 and loss of whole chromosome 10, TERT promoter mutations, and EGFR amplification, were identified as independent molecular markers of the worst clinical outcomes. Therefore, the 2021 World Health Organization (WHO) Classification of Tumors of the Central Nervous System adopted these molecular markers into the revised grading criteria of IDH-mutant and -wild-type astrocytoma, respectively, as a grading system within tumor types. Of note, several recent studies have shown that some low-grade IDH-wild-type astrocytoma lacking both the molecular glioblastoma signature and genetic alterations typical of pediatric-type gliomas may demonstrate a relatively indolent clinical course, suggesting the existence of lower-grade adult IDH-wild-type astrocytoma. In terms of oligodendroglioma, IDH-mutant, and 1p/19q codeleted, consistent makers that predict poor outcomes have not yet been identified, and, thus, the current criteria have remained unchanged. Molecular testing to fulfill the revised WHO criteria is, however, not always available worldwide, and in that case, an integrated diagnosis combining all available complementary information is highly recommended. This review discusses controversial issues surrounding legacy grading systems and newly identified potential genetic markers of adult diffuse gliomas and provides perspectives on future grading systems.The grading of gliomas based on histological features has been a subject of debate for several decades. A consensus has not yet been reached because of technical limitations and inter-observer variations. While the traditional grading system has failed to stratify the risk of IDH-mutant astrocytoma, canonical histological and proliferative markers may be applicable to the risk stratification of IDH-wild-type astrocytoma. Numerous studies have examined molecular markers in order to obtain more clinically relevant information that will improve the risk stratification of gliomas. The CDKN2A/B homozygous deletion for IDH-mutant astrocytoma and the following three criteria for IDH-wild-type astrocytoma: the concurrent gain of whole chromosome 7 and loss of whole chromosome 10, TERT promoter mutations, and EGFR amplification, were identified as independent molecular markers of the worst clinical outcomes. Therefore, the 2021 World Health Organization (WHO) Classification of Tumors of the Central Nervous System adopted these molecular markers into the revised grading criteria of IDH-mutant and -wild-type astrocytoma, respectively, as a grading system within tumor types. Of note, several recent studies have shown that some low-grade IDH-wild-type astrocytoma lacking both the molecular glioblastoma signature and genetic alterations typical of pediatric-type gliomas may demonstrate a relatively indolent clinical course, suggesting the existence of lower-grade adult IDH-wild-type astrocytoma. In terms of oligodendroglioma, IDH-mutant, and 1p/19q codeleted, consistent makers that predict poor outcomes have not yet been identified, and, thus, the current criteria have remained unchanged. Molecular testing to fulfill the revised WHO criteria is, however, not always available worldwide, and in that case, an integrated diagnosis combining all available complementary information is highly recommended. This review discusses controversial issues surrounding legacy grading systems and newly identified potential genetic markers of adult diffuse gliomas and provides perspectives on future grading systems. |
| Author | Komori, Takashi |
| Author_xml | – sequence: 1 givenname: Takashi orcidid: 0000-0002-6812-2149 surname: Komori fullname: Komori, Takashi email: komori-tk@igakuken.or.jp organization: Department of Laboratory Medicine and Pathology (Neuropathology), Tokyo Metropolitan Neurological Hospital, 2-6-1 Musashidai, 183-0042, Fuchu, Tokyo, Japan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34504304$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkc1u1DAURi1URKeFF2CBLLFhE7j-n0hs0AhapKpdUMTS8sQ3g6skbu2kUt8eZ9IKqYvpyl6c8_n6uyfkaIgDEvKewWcGYv0lSyaMrICzCkBrU-lXZMWUgAoEmCOyAuCi0mthjslJzjcATEqt3pBjIRVIAXJF7s6S82HY0dhS56dupD607ZSR7roQe5epa5qY9sgY6fgXKS8P0j_nV3TTuZxDGxo3hjjMCddTH1OebzO4wWFMrqOXmO7jlOmvhzxi_5a8bl2X8d3jeUp-__h-vTmvLq7Ofm6-XVSN4masts5LrcF4dC2TQhi2Rq22xtfag_DgNba1kKJ2fM24A2UkaC6x5QZc6UWckk9L7m2KdxPm0fYhN9h1bsAyjeXGqFpxpuFlVBlWcymFKujHZ-hNnNJQPmK55hxqpcUc-OGRmrY9enubQu_Sg33qvQDrBWhSzDlha5sw7mssjYXOMrDziu2yYlsat_sVW11U_kx9Sj8oiUXKBR52mP6PfdD6ulhY9nQfipWbgEODPiRsRutjOKT_A7a2yMY |
| CitedBy_id | crossref_primary_10_2174_1573405619666230126124039 crossref_primary_10_3389_fonc_2022_903059 crossref_primary_10_1080_19768354_2023_2175497 crossref_primary_10_3390_brainsci12121627 crossref_primary_10_7887_jcns_33_90 crossref_primary_10_1016_j_wneu_2022_03_051 crossref_primary_10_1080_14686996_2024_2426444 crossref_primary_10_32604_oncologie_2022_020890 crossref_primary_10_3390_cancers14164039 crossref_primary_10_3390_ijms24044056 crossref_primary_10_1016_j_jocn_2024_110763 crossref_primary_10_1080_10717544_2022_2075986 crossref_primary_10_3389_fonc_2022_898537 crossref_primary_10_1136_jitc_2024_009210 crossref_primary_10_1038_s41698_024_00530_z crossref_primary_10_1016_j_wneu_2022_06_074 crossref_primary_10_1002_jmri_29695 crossref_primary_10_1186_s12885_024_11996_2 crossref_primary_10_1007_s44196_023_00230_9 crossref_primary_10_1093_noajnl_vdae043 crossref_primary_10_1002_mp_17280 crossref_primary_10_3390_ijms24021405 crossref_primary_10_1038_s41467_023_41195_9 crossref_primary_10_1038_s41698_024_00762_z crossref_primary_10_1097_MD_0000000000036581 crossref_primary_10_1016_j_ajpath_2024_06_007 crossref_primary_10_3390_cancers15030596 crossref_primary_10_1007_s10334_024_01154_x crossref_primary_10_7759_cureus_57272 crossref_primary_10_3390_diagnostics12071665 crossref_primary_10_1155_2022_8638085 crossref_primary_10_1172_JCI163450 crossref_primary_10_1007_s00701_022_05301_y crossref_primary_10_1080_00207454_2024_2441994 crossref_primary_10_22328_2079_5343_2024_15_1_35_45 crossref_primary_10_1038_s41598_024_84036_5 crossref_primary_10_1111_cns_14093 crossref_primary_10_1227_neu_0000000000002260 crossref_primary_10_1016_j_canlet_2023_216265 crossref_primary_10_1021_acsomega_2c07904 crossref_primary_10_51643_22562915_677 crossref_primary_10_1002_jmri_28793 crossref_primary_10_1177_19714009231173107 crossref_primary_10_1002_jmri_28630 crossref_primary_10_3390_curroncol31040165 crossref_primary_10_1007_s10014_022_00445_2 crossref_primary_10_1016_j_brainres_2025_149529 crossref_primary_10_3390_ijms26062763 crossref_primary_10_1016_j_prp_2024_155455 crossref_primary_10_1007_s00432_023_05021_5 crossref_primary_10_1007_s10014_022_00428_3 crossref_primary_10_3390_biomedicines10020246 crossref_primary_10_3390_diagnostics12102383 crossref_primary_10_1016_j_radonc_2024_110646 crossref_primary_10_3390_biomedinformatics2030031 crossref_primary_10_1002_adhm_202300591 crossref_primary_10_1210_endrev_bnae020 crossref_primary_10_3390_biomedicines12122777 crossref_primary_10_1007_s10014_023_00474_5 crossref_primary_10_3390_brainsci13121700 crossref_primary_10_1016_j_npep_2023_102383 crossref_primary_10_1093_neuonc_noae258 crossref_primary_10_1097_CCO_0000000000001089 crossref_primary_10_32074_1591_951X_823 crossref_primary_10_3389_fonc_2023_1223199 crossref_primary_10_1007_s10278_024_01008_x crossref_primary_10_3390_antib12010014 crossref_primary_10_3389_fimmu_2023_1299064 crossref_primary_10_1016_j_soc_2022_06_002 crossref_primary_10_3390_cancers17050744 crossref_primary_10_3390_biomedicines12102237 crossref_primary_10_3389_fgene_2023_1124439 crossref_primary_10_1177_03000605221103976 crossref_primary_10_62347_WFSK7541 crossref_primary_10_1016_j_wnsx_2024_100308 crossref_primary_10_1016_j_phymed_2023_155328 crossref_primary_10_1016_j_pscia_2024_100041 crossref_primary_10_1038_s41420_023_01595_8 crossref_primary_10_1016_j_critrevonc_2024_104501 crossref_primary_10_1016_j_ijbiomac_2024_131048 crossref_primary_10_3390_cancers14163897 crossref_primary_10_3389_fonc_2022_982089 crossref_primary_10_3390_diagnostics13243610 crossref_primary_10_3390_cancers14153743 crossref_primary_10_1007_s00432_021_03906_x crossref_primary_10_1007_s12094_024_03456_x crossref_primary_10_3390_diagnostics13030363 crossref_primary_10_3389_fonc_2022_861078 crossref_primary_10_3390_life12070956 |
| Cites_doi | 10.1136/jclinpath-2017-204638 10.1007/s10014-021-00407-0 10.1186/s40478-015-0213-3 10.1093/neuonc/noz126.000 10.1093/neuonc/noaa300 10.1111/bpa.12383 10.1016/S1470-2045(12)70164-X 10.1259/bjr.20150857 10.1111/j.1750-3639.2008.00129.x 10.1186/s13148-021-01085-7 10.1007/s10014-019-00339-w 10.1007/s00401-019-01987-0 10.1038/s41374-020-00514-0 10.1111/nan.12523 10.1007/s00401-015-1409-0 10.1016/j.ccr.2010.03.017 10.1007/s10014-021-00403-4 10.1007/s00401-017-1765-z 10.1093/neuonc/noaa200 10.1111/bpa.12832 10.1007/s10014-016-0249-5 10.1186/s40478-016-0351-2 10.1038/ncomms8207 10.1038/s41379-020-00701-w 10.1111/bpa.12866 10.1056/NEJMoa043331 10.1136/jclinpath-2015-203174 10.1007/s00234-019-02173-5 10.5858/arpa.2018-0565-OA 10.1007/978-3-642-84988-6 10.3174/ajnr.A3384 10.1093/neuonc/noz052 10.1007/s10014-020-00358-y 10.1007/s00428-021-03134-1 10.1007/s10014-017-0299-3 10.1093/jnen/nlz082 10.1186/s40478-019-0778-3 10.1007/s10014-020-00375-x 10.1007/s00401-018-1808-0 10.1016/j.ccr.2010.11.015 10.1016/j.cell.2015.12.028 10.1111/j.1750-3639.2008.00192.x 10.1038/nature26000 10.1007/s10014-020-00363-1 10.1111/bpa.12171 10.1038/s41379-019-0310-0 10.5858/arpa.2011-0567-HP 10.1093/neuonc/noaa258 10.18632/oncotarget.8498 10.1073/pnas.1303607110 10.1007/s10014-019-00348-9 10.1007/s10014-013-0165-x 10.1007/s00401-015-1454-8 10.3174/ajnr.A5070 10.1056/NEJMoa1402121 10.1093/neuonc/noab106 10.1002/ca.22000 10.1007/s00401-018-1905-0 10.1007/s00401-018-1826-y 10.1097/00005072-199901000-00006 10.1007/s10014-018-0313-4 10.1038/nrneurol.2014.100 10.1007/s10014-018-0322-3 10.1007/s00401-015-1398-z 10.1007/s00401-007-0243-4 10.1126/science.1164382 10.1093/neuonc/noy048 10.1186/s40478-017-0443-7 10.1093/neuonc/nox183 10.1056/NEJMoa1407279 10.1186/s40478-019-0704-8 10.1093/jnen/nlab023 10.1007/s10014-020-00377-9 10.1007/s00401-016-1646-x 10.1111/bpa.12929 10.1007/s10014-018-0312-5 10.5858/2007-131-234-NIMITE 10.1093/neuonc/noaa041 10.1111/bpa.12801 10.1111/bpa.12043 10.3174/ajnr.A3352 10.1097/NEN.0000000000000188 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T 10.1200/JCO.1998.16.12.3851 10.1007/s00401-019-02025-9 10.1007/s00401-018-1849-4 10.1093/neuonc/noz200 10.1007/s00401-016-1545-1 10.1038/s41698-018-0067-9 10.1093/neuonc/nox132 10.1007/s00401-018-1879-y 10.1007/s10014-020-00392-w 10.1007/s10014-017-0293-9 10.1007/s10014-020-00360-4 10.1007/s10014-019-00337-y 10.1186/1746-1596-6-43 10.1007/s10014-018-0321-4 10.1093/neuonc/noab052 10.1007/s00401-021-02337-9 10.1007/s10014-019-00340-3 10.1093/jnen/60.3.248 |
| ContentType | Journal Article |
| Copyright | 2021 United States & Canadian Academy of Pathology The Author(s), under exclusive licence to United States and Canadian Academy of Pathology 2021 2021. The Author(s), under exclusive licence to United States and Canadian Academy of Pathology. The Author(s), under exclusive licence to United States and Canadian Academy of Pathology 2021. |
| Copyright_xml | – notice: 2021 United States & Canadian Academy of Pathology – notice: The Author(s), under exclusive licence to United States and Canadian Academy of Pathology 2021 – notice: 2021. The Author(s), under exclusive licence to United States and Canadian Academy of Pathology. – notice: The Author(s), under exclusive licence to United States and Canadian Academy of Pathology 2021. |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7QR 7T5 7T7 7TK 7TM 7U9 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7N M7P P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1038/s41374-021-00667-6 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Neurosciences Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Central Korea Engineering Research Database Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Biotechnology and BioEngineering Abstracts Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection Chemoreception Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Public Health ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest Central Student MEDLINE MEDLINE - Academic MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1530-0307 |
| EndPage | 133 |
| ExternalDocumentID | 34504304 10_1038_s41374_021_00667_6 S0023683722000745 |
| Genre | Journal Article Review |
| GroupedDBID | --- -Q- -~X .55 .GJ 0R~ 1KJ 29L 2WC 36B 39C 3V. 4.4 53G 5GY 5RE 6I. 70F 7X7 88E 8AO 8C1 8FI 8FJ 8R4 8R5 8WZ A6W AADWK AAFTH AANZL AAWBL AAXUO AAYFA AAYJO AAZLF ABAWZ ABCQX ABGIJ ABJNI ABLJU ABUWG ACBMV ACBRV ACBYP ACGFO ACGFS ACIGE ACIWK ACKTT ACPRK ACRQY ACTTH ACVWB ACZOJ ADBBV ADHDB ADMDM ADQMX ADYYL AEDAW AEFTE AEJRE AENEX AEXYK AFFNX AFKRA AFOSN AFRAH AFSHS AGAYW AGEZK AGGBP AGHAI AHMBA AHPSJ AHSBF AILAN AJDOV AJRNO ALFFA ALMA_UNASSIGNED_HOLDINGS AMRAJ AMRJV AMYLF ASPBG AVWKF AXYYD AZFZN BAWUL BBNVY BENPR BHPHI BKKNO BPHCQ BVXVI CAG CCPQU COF CS3 DIK DNIVK DU5 E3Z EBLON EBS EE. EIOEI EJD EMB F5P FDB FDQFY FEDTE FERAY FIZPM FSGXE FYUFA GX1 HCIFZ HMCUK HVGLF HZ~ IH2 IWAJR JSO JZLTJ KQ8 M1P M7P MVM NAO NQJWS NYICJ O9- OK1 P2P P6G PQQKQ PROAC PSQYO Q2X RNS RNT RNTTT ROL S10 SNX SNYQT SOHCF SRMVM SV3 SWTZT TAOOD TBHMF TDRGL TR2 TSG TWZ UKHRP X7M Y6R YFH YKV YOC YQI YQT ZA5 ZGI ZXP AAHOK AALRI ADVLN AFJKZ AITUG AKRWK ALIPV PKN AAYWO AAYXX ACVFH ADCNI ADXHL AEUPX AFPUW AIGII AKBMS AKYEP APXCP CITATION EFKBS PHGZM PHGZT PJZUB PPXIY PQGLB PUEGO CGR CUY CVF ECM EIF NPM 7QL 7QP 7QR 7T5 7T7 7TK 7TM 7U9 7XB 8FD 8FE 8FH 8FK AGCQF AZQEC C1K DWQXO FR3 GNUQQ H94 K9. LK8 M7N P64 PKEHL PQEST PQUKI PRINS 7X8 |
| ID | FETCH-LOGICAL-c527t-bad46607deaf1433718e65b7d96d03d0d6ef93439a2812a05740624ef270a1373 |
| IEDL.DBID | 7X7 |
| ISSN | 0023-6837 1530-0307 |
| IngestDate | Sun Sep 28 11:22:22 EDT 2025 Sun Sep 28 11:19:19 EDT 2025 Fri Jul 25 19:39:38 EDT 2025 Thu Apr 03 06:52:32 EDT 2025 Thu Apr 24 23:04:39 EDT 2025 Thu Sep 25 00:51:25 EDT 2025 Fri Feb 21 02:38:03 EST 2025 Fri Feb 23 02:39:22 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | This article is made available under the Elsevier license. 2021. The Author(s), under exclusive licence to United States and Canadian Academy of Pathology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c527t-bad46607deaf1433718e65b7d96d03d0d6ef93439a2812a05740624ef270a1373 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 ObjectType-Article-2 ObjectType-Feature-3 ObjectType-Review-1 |
| ORCID | 0000-0002-6812-2149 |
| OpenAccessLink | https://dx.doi.org/10.1038/s41374-021-00667-6 |
| PMID | 34504304 |
| PQID | 2622095630 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_2775952160 proquest_miscellaneous_2571924435 proquest_journals_2622095630 pubmed_primary_34504304 crossref_citationtrail_10_1038_s41374_021_00667_6 crossref_primary_10_1038_s41374_021_00667_6 springer_journals_10_1038_s41374_021_00667_6 elsevier_sciencedirect_doi_10_1038_s41374_021_00667_6 |
| PublicationCentury | 2000 |
| PublicationDate | February 2022 20220200 2022-02-00 20220201 |
| PublicationDateYYYYMMDD | 2022-02-01 |
| PublicationDate_xml | – month: 02 year: 2022 text: February 2022 |
| PublicationDecade | 2020 |
| PublicationPlace | New York |
| PublicationPlace_xml | – name: New York – name: United States |
| PublicationSubtitle | Advancing the understanding of human and experimental disease |
| PublicationTitle | Laboratory investigation |
| PublicationTitleAbbrev | Lab Invest |
| PublicationTitleAlternate | Lab Invest |
| PublicationYear | 2022 |
| Publisher | Elsevier Inc Nature Publishing Group US Nature Publishing Group |
| Publisher_xml | – name: Elsevier Inc – name: Nature Publishing Group US – name: Nature Publishing Group |
| References | Kuwahara (bib51) 2019; 36 Fukai (bib72) 2020; 37 Cui, Zhang (bib107) 2021; 101 Etienne (bib9) 2012; 25 Appay (bib45) 2019; 21 Phillips (bib47) 2013; 23 Komori (bib66) 2021; 38 Chawla (bib95) 2013; 34 (2021). Andreiuolo, Mazeraud, Chretien, Pietsch (bib84) 2016; 26 Olar (bib32) 2015; 129 Capper (bib106) 2018; 555 Killela (bib27) 2013; 110 Louis, von Deimling (bib6) 2017; 134 Richardson, Hatanpaa, Walker (bib54) 2021; 80 Takei, Bhattacharjee, Rivera, Dancer, Powell (bib16) 2007; 131 Duregon (bib19) 2016; 7 Shirahata (bib44) 2018; 136 Scheithauer (bib10) 2009; 19 Adachi (bib80) 2021; 38 Aoki, Natsume (bib75) 2019; 36 Kleihues, P., Burger, P. C., Scheithauer, B. W. WHO Classification of Tumours Editorial Board. Wright, Albert (bib8) 2012; 136 Habberstad, Gulati, Torp (bib17) 2011; 6 . Binder (bib38) 2019; 7 Malta (bib74) 2018; 20 Cimino (bib41) 2017; 5 Satomi (bib105) 2021; 34 Hegi (bib68) 2005; 352 Suzuki (bib18) 2017; 34 Fujimoto (bib57) 2021; 142 Woo (bib76) 2020; 37 Sonoda (bib86) 2019; 36 (World Health Organization classification of tumors, IARC Press, Lyon, France, 2000). Stichel (bib49) 2018; 136 Aoki (bib46) 2018; 20 Giannini, Giangaspero (bib56) 2021; 23 Latysheva (bib93) 2019; 61 Ammendola, S., et al. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology. Li (bib36) 2019; 1 Natsumeda, M., et al. Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features. Jain (bib97) 2020; 22 (International Agency for Research on Cancer, Lyon, 2016). Capper (bib53) 2018; 136 Arima (bib22) 2016; 69 Louis (bib85) 2014; 24 Filipski (bib100) 2019; 138 (Elsevier, Philadelphia, 2018). (International Agency for Research on Cancer, Lyon, 2021) in press. (Springer-Verlag, Berlin, 1993). Friedman (bib70) 1998; 16 Yang (bib35) 2019; 30 Miki (bib81) 2020; 37 Louis (bib24) 2020; 30 Louis, D. N., Ohgaki H., Wiestler O. D., Cavenee W. K. Ostrom (bib64) 2020; 22 Reuss (bib52) 2015; 130 Noushmehr (bib73) 2010; 17 Louis (bib14) 2007; 114 Ferreyra Vega (bib40) 2021; 13 Berzero (bib55) 2021; 23 Zülch, K. J. Eckel-Passow (bib30) 2015; 372 Yoda (bib33) 2019; 78 Giannini (bib21) 1999; 58 Komori (bib5) 2020; 37 Ellison (bib67) 2020; 30 Ceccarelli (bib39) 2016; 164 So, Mamatjan, Zadeh, Aldape, Moraes (bib63) 2021; 23 Giannini (bib59) 2001; 60 Tateishi, Nakamura, Yamamoto (bib65) 2019; 36 Roux (bib90) 2021; 31 Akagi (bib3) 2018; 35 Yokogami (bib82) 2018; 35 Louis (bib23) 2017; 133 Kleihues, P., Cavenee, W. K. Mirchia (bib79) 2019; 7 Wick (bib69) 2014; 10 Tesileanu (bib50) 2020; 22 Chapel (bib104) 2020; 33 Louis (bib26) 2016; 131 Labreche (bib62) 2015; 6 Johnson (bib91) 2017; 38 Smits (bib92) 2016; 89 Brat, Verhaak, Aldape, Yung, Salama (bib31) 2015; 372 Ellison (bib77) 2019; 137 Broen (bib96) 2018; 20 Weller (bib48) 2015; 129 Komori (bib60) 2013; 30 Ohba, Kuwahara, Yamada, Abe, Hirose (bib4) 2020; 37 Arita (bib28) 2016; 4 Korshunov (bib37) 2019; 45 (World Health Organization, Geneva, 1979). Reis (bib43) 2015; 74 Cimino, Holland (bib42) 2019; 21 Daumas-Duport, Scheithauer, O'Fallon, Kelly (bib13) 1988; 62 Figueroa (bib29) 2010; 18 Rajeswarie, Rao, Nandeesh, Yasha, Santosh (bib87) 2018; 71 Louis (bib103) 2018; 135 Giannini (bib58) 2008; 18 Komori (bib2) 2017; 34 Perry, A., Brat D. J. Louis (bib83) 2020; 144 2021 Halani (bib61) 2018; 2 Louis (bib34) 2021; 23 Wick (bib71) 2012; 13 Yamauchi (bib88) 2018; 35 Yamamichi (bib101) 2018; 35 Saito (bib98) 2016; 33 Parsons (bib25) 2008; 321 Louis (bib102) 2018; 135 Cohen (bib78) 2015; 3 Fellah (bib94) 2013; 34 LouisDNThe 2007 WHO classification of tumours of the central nervous systemActa Neuropathol.20071149710917618441192916510.1007/s00401-007-0243-4 FukaiJMolecular characteristics and clinical outcomes of elderly patients with IDH-wild-type glioblastomas: comparative study of older and younger cases in Kansai Network cohortBrain Tumor Pathol.20203750591:CAS:528:DC%2BB3cXos1Gitbs%3D3236194110.1007/s10014-020-00363-1 GianniniCAnaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402Brain Pathol.20081836036918371182809553510.1111/j.1750-3639.2008.00129.x GianniniCCellular proliferation in pilocytic and diffuse astrocytomasJ. Neuropathol. Exp. Neurol.19995846531:STN:280:DyaK1M7jvF2isQ%3D%3D1006831310.1097/00005072-199901000-00006 SonodaYPractical procedures for the integrated diagnosis of astrocytic and oligodendroglial tumorsBrain Tumor Pathol.20193656621:CAS:528:DC%2BC1MXhtVCjtbjP3084771110.1007/s10014-019-00337-y AokiKPrognostic relevance of genetic alterations in diffuse lower-grade gliomasNeuro Oncol.20182066771:CAS:528:DC%2BC1MXps1Ogtr0%3D2901683910.1093/neuonc/nox132 KorshunovAIntegrated molecular characterization of IDH-mutant glioblastomasNeuropathol. Appl. Neurobiol.2019451081181:CAS:528:DC%2BC1MXjtFKmtr4%3D3032616310.1111/nan.12523 Kleihues, P., Burger, P. C., Scheithauer, B. W. Histological Typing of Tumours of the Central Nevous System (Springer-Verlag, Berlin, 1993). CiminoPJHollandECTargeted copy number analysis outperforms histological grading in predicting patient survival for WHO grade II/III IDH-mutant astrocytomasNeuro Oncol.20192181982130918961655684110.1093/neuonc/noz052 WickWMGMT testing–the challenges for biomarker-based glioma treatmentNat. Rev. Neurol.2014103723851:CAS:528:DC%2BC2cXpslChsbY%3D2491251210.1038/nrneurol.2014.100 MikiSHighly sensitive detection of TERT promoter mutations in recurrent glioblastomas using digital PCRBrain Tumor Pathol.2020371541581:CAS:528:DC%2BB3cXhsFegt73L3274962410.1007/s10014-020-00375-x Ferreyra VegaSDNA methylation profiling for molecular classification of adult diffuse lower-grade gliomasClin Epigenet.2021131021131:CAS:528:DC%2BB3MXhtlSrs73P10.1186/s13148-021-01085-7 KomoriTControversies over the diagnosis of oligodendroglioma: a report from the satellite workshop at the 4th international symposium of brain tumor pathology, Nagoya Congress Center, May 23, 2012Brain Tumor Pathol.2013302532612410079410.1007/s10014-013-0165-x WellerMMolecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groupsActa Neuropathol.20151296796931:CAS:528:DC%2BC2MXltVWlsLY%3D2578374710.1007/s00401-015-1409-0 Ammendola, S., et al. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology. Virchows Arch. https://doi.org/10.1007/s00428-021-03134-1 (2021). KomoriTUpdated 2016 WHO classification of tumors of the CNS: turning the corner where molecule meets pathologyBrain Tumor Pathol.2017341391402884040310.1007/s10014-017-0299-3 Daumas-DuportCScheithauerBO’FallonJKellyPGrading of astrocytomas. A simple and reproducible methodCancer198862215221651:STN:280:DyaL1M%2FivVSqtg%3D%3D317992810.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T Zülch, K. J. Histological Typing of Tumours of the Central Nervous System (World Health Organization, Geneva, 1979). CohenADNA copy number analysis of grade II–III and grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation statusActa Neuropathol. Commun.20153344626091668447435110.1186/s40478-015-0213-31:CAS:528:DC%2BC28XpsV2mtLg%3D StichelDDistribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastomaActa Neuropathol.20181367938033018712110.1007/s00401-018-1905-0 Eckel-PassowJEGlioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumorsN. Engl. J. Med.2015372249925081:CAS:528:DC%2BC2MXhtFyrsbvO26061753448970410.1056/NEJMoa1407279 SatomiKUtility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytomaMod. Pathol.2021346887001:CAS:528:DC%2BB3cXitFWjurfF3307792410.1038/s41379-020-00701-w HabberstadAHGulatiSTorpSHEvaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIalpha in human anaplastic astrocytomas–an immunohistochemical studyDiagn. Pathol.20116435121609421312781510.1186/1746-1596-6-43 AppayRCDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomasNeuro Oncol.201921151915281:CAS:528:DC%2BB3cXhvFers7%2FI31832685714556110.1093/neuonc/noz126.000 YamamichiAImmunohistochemical ATRX expression is not a surrogate for 1p19q codeletionBrain Tumor Pathol.2018351061131:CAS:528:DC%2BC1cXltVKgu7w%3D2955088010.1007/s10014-018-0312-5 EtienneDJames Watson Kernohan (1896-198): frontiers in neuropathologyClin. Anat.2012255275292233160110.1002/ca.22000 SuzukiAModified rapid immunohistochemical staining for intraoperative diagnosis of malignant brain tumorsBrain Tumor Pathol.2017341411481:CAS:528:DC%2BC2sXhtlKnu77J2882309810.1007/s10014-017-0293-9 OstromQTCBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017Neuro Oncol.202022iv1iv9633123732759624710.1093/neuonc/noaa200 EllisonDWcIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF(V600E) mutationActa Neuropathol.20191376836871:CAS:528:DC%2BC1MXmslKisrw%3D3084834710.1007/s00401-019-01987-0 LouisDNcIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC)Acta Neuropathol.20181354814842937231810.1007/s00401-018-1808-0 ArimaNThe importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 indexJ. Clin. Pathol.2016692552591:CAS:528:DC%2BC28XhtlWnurjK2642076710.1136/jclinpath-2015-203174 YokogamiKImpact of PCR-based molecular analysis in daily diagnosis for the patient with gliomasBrain Tumor Pathol.2018351411471:CAS:528:DC%2BC1cXht1ekur3M2993148510.1007/s10014-018-0322-3 WrightJRAlbertCJrBroders’ paradigm shifts involving the prognostication and definition of cancerArch. Pathol. Lab. Med.2012136143714462310659010.5858/arpa.2011-0567-HP FujimotoKTERT promoter mutation status is necessary and sufficient to diagnose IDH-wild-type diffuse astrocytic glioma with molecular features of glioblastomaActa Neuropathol.20211423233381:CAS:528:DC%2BB3MXhsFOgt7rK3414810510.1007/s00401-021-02337-9 KomoriTThe molecular framework of pediatric-type diffuse gliomas: shifting toward the revision of the WHO classification of tumors of the central nervous systemBrain Tumor Pathol.202138133339847210.1007/s10014-020-00392-w FellahSMultimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis?Am. J. Neuroradiol.201334132613331:STN:280:DC%2BC3s7pvVansQ%3D%3D23221948805148710.3174/ajnr.A3352 LouisDNData sets for the reporting of tumors of the central nervous system: recommendations from the International Collaboration on Cancer ReportingArch. Pathol. Lab. Med.20201441962063121934410.5858/arpa.2018-0565-OA LouisDNcIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutantActa Neuropathol.20181356396422949781910.1007/s00401-018-1826-y FilipskiKLack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomasActa Neuropathol.201913833133431065834666049810.1007/s00401-019-02025-9 LiKKIdentification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risksNeurooncol. Adv.20191111 AkagiYReclassification of 400 consecutive glioma cases based on the revised 2016WHO classificationBrain Tumor Pathol.20183581891:CAS:528:DC%2BC1cXlslSlsr8%3D2956916310.1007/s10014-018-0313-4 BinderHDNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and developmentActa Neuropathol. Commun.20197591:STN:280:DC%2BB3M%2Fpt1GnsQ%3D%3D31023364648257310.1186/s40478-019-0704-8 CiminoPJMultidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discoveryActa Neuropathol. Commun.20175395328532485543911710.1186/s40478-017-0443-71:CAS:528:DC%2BC1cXhvFaqtLjN SmitsMImaging of oligodendrogliomaBr. J. Radiol.2016892015085726849038484621310.1259/bjr.20150857 LabrecheKTCF12 is mutated in anaplastic oligodendrogliomaNat. Commun.20156720772161:CAS:528:DC%2BC2MXhtF2ktrnI2606820110.1038/ncomms8207 SaitoTCalcification on CT is a simple and valuable preoperative indicator of 1p/19q loss of heterozygosity in supratentorial brain tumors that are suspected grade II and III gliomasBrain Tumor Pathol.2016331751821:CAS:528:DC%2BC28Xit12ksLg%3D2684937310.1007/s10014-016-0249-5 DuregonEKi-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomasOncotarget201672190219810.18632/oncotarget.8498 JohnsonDRGenetically defined oligodendroglioma is characterized by indistinct tumor borders at MRIAm. J. Neuroradiol.2017386786841:STN:280:DC%2BC1c7ps1Kltw%3D%3D28126746796025410.3174/ajnr.A5070 RouxAPrognostic relevance of adding MRI data to WHO 2016 and cIMPACT-NOW updates for diffuse astrocytic tumors in adults. Working toward the extended use of MRI data in integrated glioma diagnosisBrain Pathol.202131e129291:CAS Louis (10.1038/s41374-021-00667-6_bib26) 2016; 131 10.1038/s41374-021-00667-6_bib7 Ellison (10.1038/s41374-021-00667-6_bib77) 2019; 137 10.1038/s41374-021-00667-6_bib1 Richardson (10.1038/s41374-021-00667-6_bib54) 2021; 80 Komori (10.1038/s41374-021-00667-6_bib60) 2013; 30 Louis (10.1038/s41374-021-00667-6_bib83) 2020; 144 Appay (10.1038/s41374-021-00667-6_bib45) 2019; 21 Louis (10.1038/s41374-021-00667-6_bib102) 2018; 135 Aoki (10.1038/s41374-021-00667-6_bib75) 2019; 36 Yokogami (10.1038/s41374-021-00667-6_bib82) 2018; 35 Binder (10.1038/s41374-021-00667-6_bib38) 2019; 7 Cui (10.1038/s41374-021-00667-6_bib107) 2021; 101 Figueroa (10.1038/s41374-021-00667-6_bib29) 2010; 18 Duregon (10.1038/s41374-021-00667-6_bib19) 2016; 7 Reis (10.1038/s41374-021-00667-6_bib43) 2015; 74 So (10.1038/s41374-021-00667-6_bib63) 2021; 23 Filipski (10.1038/s41374-021-00667-6_bib100) 2019; 138 Ohba (10.1038/s41374-021-00667-6_bib4) 2020; 37 Tateishi (10.1038/s41374-021-00667-6_bib65) 2019; 36 Arima (10.1038/s41374-021-00667-6_bib22) 2016; 69 Yang (10.1038/s41374-021-00667-6_bib35) 2019; 30 Louis (10.1038/s41374-021-00667-6_bib14) 2007; 114 Tesileanu (10.1038/s41374-021-00667-6_bib50) 2020; 22 Louis (10.1038/s41374-021-00667-6_bib24) 2020; 30 Rajeswarie (10.1038/s41374-021-00667-6_bib87) 2018; 71 Woo (10.1038/s41374-021-00667-6_bib76) 2020; 37 Louis (10.1038/s41374-021-00667-6_bib103) 2018; 135 Saito (10.1038/s41374-021-00667-6_bib98) 2016; 33 Akagi (10.1038/s41374-021-00667-6_bib3) 2018; 35 Aoki (10.1038/s41374-021-00667-6_bib46) 2018; 20 Giannini (10.1038/s41374-021-00667-6_bib21) 1999; 58 Halani (10.1038/s41374-021-00667-6_bib61) 2018; 2 Ferreyra Vega (10.1038/s41374-021-00667-6_bib40) 2021; 13 Louis (10.1038/s41374-021-00667-6_bib23) 2017; 133 Capper (10.1038/s41374-021-00667-6_bib53) 2018; 136 Habberstad (10.1038/s41374-021-00667-6_bib17) 2011; 6 Daumas-Duport (10.1038/s41374-021-00667-6_bib13) 1988; 62 Chapel (10.1038/s41374-021-00667-6_bib104) 2020; 33 Giannini (10.1038/s41374-021-00667-6_bib58) 2008; 18 Chawla (10.1038/s41374-021-00667-6_bib95) 2013; 34 Andreiuolo (10.1038/s41374-021-00667-6_bib84) 2016; 26 Reuss (10.1038/s41374-021-00667-6_bib52) 2015; 130 10.1038/s41374-021-00667-6_bib12 Ellison (10.1038/s41374-021-00667-6_bib67) 2020; 30 10.1038/s41374-021-00667-6_bib11 10.1038/s41374-021-00667-6_bib99 Arita (10.1038/s41374-021-00667-6_bib28) 2016; 4 Phillips (10.1038/s41374-021-00667-6_bib47) 2013; 23 Friedman (10.1038/s41374-021-00667-6_bib70) 1998; 16 Fellah (10.1038/s41374-021-00667-6_bib94) 2013; 34 Brat (10.1038/s41374-021-00667-6_bib31) 2015; 372 Yamauchi (10.1038/s41374-021-00667-6_bib88) 2018; 35 Louis (10.1038/s41374-021-00667-6_bib6) 2017; 134 10.1038/s41374-021-00667-6_bib15 Noushmehr (10.1038/s41374-021-00667-6_bib73) 2010; 17 Scheithauer (10.1038/s41374-021-00667-6_bib10) 2009; 19 Mirchia (10.1038/s41374-021-00667-6_bib79) 2019; 7 Yamamichi (10.1038/s41374-021-00667-6_bib101) 2018; 35 Ostrom (10.1038/s41374-021-00667-6_bib64) 2020; 22 Johnson (10.1038/s41374-021-00667-6_bib91) 2017; 38 10.1038/s41374-021-00667-6_bib20 Capper (10.1038/s41374-021-00667-6_bib106) 2018; 555 Komori (10.1038/s41374-021-00667-6_bib2) 2017; 34 Jain (10.1038/s41374-021-00667-6_bib97) 2020; 22 Ceccarelli (10.1038/s41374-021-00667-6_bib39) 2016; 164 Cimino (10.1038/s41374-021-00667-6_bib42) 2019; 21 Shirahata (10.1038/s41374-021-00667-6_bib44) 2018; 136 Li (10.1038/s41374-021-00667-6_bib36) 2019; 1 Fukai (10.1038/s41374-021-00667-6_bib72) 2020; 37 Broen (10.1038/s41374-021-00667-6_bib96) 2018; 20 Fujimoto (10.1038/s41374-021-00667-6_bib57) 2021; 142 Giannini (10.1038/s41374-021-00667-6_bib59) 2001; 60 Hegi (10.1038/s41374-021-00667-6_bib68) 2005; 352 Smits (10.1038/s41374-021-00667-6_bib92) 2016; 89 Louis (10.1038/s41374-021-00667-6_bib85) 2014; 24 Miki (10.1038/s41374-021-00667-6_bib81) 2020; 37 Satomi (10.1038/s41374-021-00667-6_bib105) 2021; 34 Cimino (10.1038/s41374-021-00667-6_bib41) 2017; 5 Killela (10.1038/s41374-021-00667-6_bib27) 2013; 110 Roux (10.1038/s41374-021-00667-6_bib90) 2021; 31 Korshunov (10.1038/s41374-021-00667-6_bib37) 2019; 45 Louis (10.1038/s41374-021-00667-6_bib34) 2021; 23 Cohen (10.1038/s41374-021-00667-6_bib78) 2015; 3 Sonoda (10.1038/s41374-021-00667-6_bib86) 2019; 36 Wick (10.1038/s41374-021-00667-6_bib69) 2014; 10 Yoda (10.1038/s41374-021-00667-6_bib33) 2019; 78 Kuwahara (10.1038/s41374-021-00667-6_bib51) 2019; 36 Weller (10.1038/s41374-021-00667-6_bib48) 2015; 129 Adachi (10.1038/s41374-021-00667-6_bib80) 2021; 38 Berzero (10.1038/s41374-021-00667-6_bib55) 2021; 23 Latysheva (10.1038/s41374-021-00667-6_bib93) 2019; 61 Suzuki (10.1038/s41374-021-00667-6_bib18) 2017; 34 Takei (10.1038/s41374-021-00667-6_bib16) 2007; 131 Parsons (10.1038/s41374-021-00667-6_bib25) 2008; 321 Wick (10.1038/s41374-021-00667-6_bib71) 2012; 13 Giannini (10.1038/s41374-021-00667-6_bib56) 2021; 23 10.1038/s41374-021-00667-6_bib89 Etienne (10.1038/s41374-021-00667-6_bib9) 2012; 25 Eckel-Passow (10.1038/s41374-021-00667-6_bib30) 2015; 372 Stichel (10.1038/s41374-021-00667-6_bib49) 2018; 136 Labreche (10.1038/s41374-021-00667-6_bib62) 2015; 6 Olar (10.1038/s41374-021-00667-6_bib32) 2015; 129 Malta (10.1038/s41374-021-00667-6_bib74) 2018; 20 Wright (10.1038/s41374-021-00667-6_bib8) 2012; 136 Komori (10.1038/s41374-021-00667-6_bib66) 2021; 38 Komori (10.1038/s41374-021-00667-6_bib5) 2020; 37 |
| References_xml | – reference: (Springer-Verlag, Berlin, 1993). – volume: 7 start-page: 59 year: 2019 ident: bib38 article-title: DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development publication-title: Acta Neuropathol. Commun. – volume: 372 start-page: 2499 year: 2015 end-page: 2508 ident: bib30 article-title: Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors publication-title: N. Engl. J. Med. – volume: 31 start-page: e12929 year: 2021 ident: bib90 article-title: Prognostic relevance of adding MRI data to WHO 2016 and cIMPACT-NOW updates for diffuse astrocytic tumors in adults. Working toward the extended use of MRI data in integrated glioma diagnosis publication-title: Brain Pathol. – volume: 22 start-page: iv1 year: 2020 end-page: iv96 ident: bib64 article-title: CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017 publication-title: Neuro Oncol. – volume: 17 start-page: 510 year: 2010 end-page: 522 ident: bib73 article-title: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma publication-title: Cancer Cell – volume: 71 start-page: 323 year: 2018 end-page: 329 ident: bib87 article-title: A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up publication-title: J. Clin. Pathol. – volume: 21 start-page: 1519 year: 2019 end-page: 1528 ident: bib45 article-title: CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas publication-title: Neuro Oncol. – volume: 78 start-page: 1002 year: 2019 end-page: 1010 ident: bib33 article-title: Mitotic index thresholds do not predict clinical outcome for IDH-mutant astrocytoma publication-title: J. Neuropathol. Exp. Neurol. – volume: 110 start-page: 6021 year: 2013 end-page: 6026 ident: bib27 article-title: TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal publication-title: Proc. Natl Acad. Sci. USA – volume: 23 start-page: 865 year: 2021 end-page: 866 ident: bib56 article-title: TERT promoter mutation: is it enough to call a WHO grade II astrocytoma IDH wild-type glioblastoma? publication-title: Neuro Oncol. – volume: 89 start-page: 20150857 year: 2016 ident: bib92 article-title: Imaging of oligodendroglioma publication-title: Br. J. Radiol. – volume: 38 start-page: 201 year: 2021 end-page: 209 ident: bib80 article-title: Droplet digital PCR assay for detecting TERT promoter mutations in patients with glioma publication-title: Brain Tumor Pathol. – volume: 130 start-page: 407 year: 2015 end-page: 417 ident: bib52 article-title: Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities publication-title: Acta Neuropathol. – volume: 7 start-page: 2190 year: 2016 end-page: 2198 ident: bib19 article-title: Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas publication-title: Oncotarget – volume: 38 start-page: 1 year: 2021 end-page: 3 ident: bib66 article-title: The molecular framework of pediatric-type diffuse gliomas: shifting toward the revision of the WHO classification of tumors of the central nervous system publication-title: Brain Tumor Pathol. – volume: 35 start-page: 106 year: 2018 end-page: 113 ident: bib101 article-title: Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion publication-title: Brain Tumor Pathol. – volume: 18 start-page: 360 year: 2008 end-page: 369 ident: bib58 article-title: Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402 publication-title: Brain Pathol. – reference: (2021). – reference: Perry, A., Brat D. J. – volume: 131 start-page: 803 year: 2016 end-page: 820 ident: bib26 article-title: The 2016 World Health Organization classification of tumors of the central nervous system: a summary publication-title: Acta Neuropathol. – volume: 16 start-page: 3851 year: 1998 end-page: 3857 ident: bib70 article-title: DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma publication-title: J. Clin. Oncol. – volume: 34 start-page: 1326 year: 2013 end-page: 1333 ident: bib94 article-title: Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis? publication-title: Am. J. Neuroradiol. – volume: 35 start-page: 141 year: 2018 end-page: 147 ident: bib82 article-title: Impact of PCR-based molecular analysis in daily diagnosis for the patient with gliomas publication-title: Brain Tumor Pathol. – reference: (International Agency for Research on Cancer, Lyon, 2021) in press. – volume: 36 start-page: 84 year: 2019 end-page: 91 ident: bib75 article-title: Overview of DNA methylation in adult diffuse gliomas publication-title: Brain Tumor Pathol. – volume: 30 start-page: 844 year: 2020 end-page: 856 ident: bib24 article-title: cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading publication-title: Brain Pathol. – volume: 10 start-page: 372 year: 2014 end-page: 385 ident: bib69 article-title: MGMT testing–the challenges for biomarker-based glioma treatment publication-title: Nat. Rev. Neurol. – volume: 37 start-page: 1 year: 2020 end-page: 4 ident: bib5 article-title: Updating the grading criteria for adult diffuse gliomas: beyond the WHO2016CNS classification publication-title: Brain Tumor Pathol. – volume: 135 start-page: 481 year: 2018 end-page: 484 ident: bib102 article-title: cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC) publication-title: Acta Neuropathol. – volume: 30 start-page: 541 year: 2019 end-page: 553 ident: bib35 article-title: IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations publication-title: Brain Pathol. – volume: 142 start-page: 323 year: 2021 end-page: 338 ident: bib57 article-title: TERT promoter mutation status is necessary and sufficient to diagnose IDH-wild-type diffuse astrocytic glioma with molecular features of glioblastoma publication-title: Acta Neuropathol. – volume: 555 start-page: 469 year: 2018 end-page: 474 ident: bib106 article-title: DNA methylation-based classification of central nervous system tumours publication-title: Nature – volume: 61 start-page: 545 year: 2019 end-page: 555 ident: bib93 article-title: Dynamic susceptibility contrast and diffusion MR imaging identify oligodendroglioma as defined by the 2016 WHO classification for brain tumors: histogram analysis approach publication-title: Neuroradiology – volume: 372 start-page: 2481 year: 2015 end-page: 2498 ident: bib31 article-title: Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas publication-title: N. Engl. J. Med. – volume: 37 start-page: 154 year: 2020 end-page: 158 ident: bib81 article-title: Highly sensitive detection of TERT promoter mutations in recurrent glioblastomas using digital PCR publication-title: Brain Tumor Pathol. – volume: 138 start-page: 331 year: 2019 end-page: 334 ident: bib100 article-title: Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas publication-title: Acta Neuropathol. – volume: 60 start-page: 248 year: 2001 end-page: 262 ident: bib59 article-title: Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading publication-title: J. Neuropathol. Exp. Neurol. – volume: 3 start-page: 34 year: 2015 end-page: 46 ident: bib78 article-title: DNA copy number analysis of grade II–III and grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status publication-title: Acta Neuropathol. Commun. – volume: 4 start-page: 79 year: 2016 end-page: 93 ident: bib28 article-title: A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas publication-title: Acta Neuropathol. Commun. – volume: 35 start-page: 81 year: 2018 end-page: 89 ident: bib3 article-title: Reclassification of 400 consecutive glioma cases based on the revised 2016WHO classification publication-title: Brain Tumor Pathol. – volume: 33 start-page: 175 year: 2016 end-page: 182 ident: bib98 article-title: Calcification on CT is a simple and valuable preoperative indicator of 1p/19q loss of heterozygosity in supratentorial brain tumors that are suspected grade II and III gliomas publication-title: Brain Tumor Pathol. – volume: 22 start-page: 515 year: 2020 end-page: 523 ident: bib50 article-title: Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria publication-title: Neuro Oncol. – volume: 6 start-page: 7207 year: 2015 end-page: 7216 ident: bib62 article-title: TCF12 is mutated in anaplastic oligodendroglioma publication-title: Nat. Commun. – volume: 23 start-page: 955 year: 2021 end-page: 966 ident: bib55 article-title: IDH-wild-type lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification publication-title: Neuro Oncol. – volume: 23 start-page: 1231 year: 2021 end-page: 1251 ident: bib34 article-title: The 2021 WHO classification of tumors of the central nervous system: a summary publication-title: Neuro Oncol. – reference: (International Agency for Research on Cancer, Lyon, 2016). – reference: (Elsevier, Philadelphia, 2018). – volume: 36 start-page: 74 year: 2019 end-page: 83 ident: bib65 article-title: Molecular genetics and therapeutic targets of pediatric low-grade gliomas publication-title: Brain Tumor Pathol. – volume: 7 start-page: 121 year: 2019 end-page: 124 ident: bib79 article-title: Establishing a prognostic threshold for total copy number variation within adult IDH-mutant grade II/III astrocytomas publication-title: Acta Neuropathol. Commun. – volume: 164 start-page: 550 year: 2016 end-page: 563 ident: bib39 article-title: Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma publication-title: Cell – volume: 36 start-page: 135 year: 2019 end-page: 143 ident: bib51 article-title: Clinical, histopathological, and molecular analyses of IDH-wild-type WHO grade II–III gliomas to establish genetic predictors of poor prognosis publication-title: Brain Tumor Pathol. – volume: 38 start-page: 678 year: 2017 end-page: 684 ident: bib91 article-title: Genetically defined oligodendroglioma is characterized by indistinct tumor borders at MRI publication-title: Am. J. Neuroradiol. – volume: 24 start-page: 429 year: 2014 end-page: 435 ident: bib85 article-title: International Society Of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading publication-title: Brain Pathol. – volume: 136 start-page: 1437 year: 2012 end-page: 1446 ident: bib8 article-title: Broders' paradigm shifts involving the prognostication and definition of cancer publication-title: Arch. Pathol. Lab. Med. – volume: 34 start-page: 688 year: 2021 end-page: 700 ident: bib105 article-title: Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma publication-title: Mod. Pathol. – volume: 135 start-page: 639 year: 2018 end-page: 642 ident: bib103 article-title: cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant publication-title: Acta Neuropathol. – volume: 136 start-page: 793 year: 2018 end-page: 803 ident: bib49 article-title: Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma publication-title: Acta Neuropathol. – reference: (2021) – volume: 37 start-page: 136 year: 2020 end-page: 144 ident: bib76 article-title: Glioblastomas harboring gene fusions detected by next-generation sequencing publication-title: Brain Tumor Pathol. – volume: 352 start-page: 997 year: 2005 end-page: 1003 ident: bib68 article-title: MGMT gene silencing and benefit from temozolomide in glioblastoma publication-title: N. Engl. J. Med. – volume: 144 start-page: 196 year: 2020 end-page: 206 ident: bib83 article-title: Data sets for the reporting of tumors of the central nervous system: recommendations from the International Collaboration on Cancer Reporting publication-title: Arch. Pathol. Lab. Med. – volume: 23 start-page: 795 year: 2021 end-page: 802 ident: bib63 article-title: Transcription factor networks of oligodendrogliomas treated with adjuvant radiotherapy or observation inform prognosis publication-title: Neuro Oncol. – volume: 2 start-page: 24 year: 2018 end-page: 33 ident: bib61 article-title: Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways publication-title: NPJ Precis. Oncol. – volume: 137 start-page: 683 year: 2019 end-page: 687 ident: bib77 article-title: cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF(V600E) mutation publication-title: Acta Neuropathol. – volume: 20 start-page: 1393 year: 2018 end-page: 1399 ident: bib96 article-title: The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study publication-title: Neuro Oncol. – volume: 37 start-page: 50 year: 2020 end-page: 59 ident: bib72 article-title: Molecular characteristics and clinical outcomes of elderly patients with IDH-wild-type glioblastomas: comparative study of older and younger cases in Kansai Network cohort publication-title: Brain Tumor Pathol. – reference: Zülch, K. J. – reference: Kleihues, P., Cavenee, W. K. – volume: 5 start-page: 39 year: 2017 end-page: 53 ident: bib41 article-title: Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery publication-title: Acta Neuropathol. Commun. – volume: 30 start-page: 863 year: 2020 end-page: 866 ident: bib67 article-title: cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors publication-title: Brain Pathol. – reference: (World Health Organization classification of tumors, IARC Press, Lyon, France, 2000). – volume: 80 start-page: 431 year: 2021 end-page: 435 ident: bib54 article-title: Molecular characterization of “True” low-grade IDH-wild-type astrocytomas publication-title: J. Neuropathol. Exp. Neurol. – volume: 20 start-page: 66 year: 2018 end-page: 77 ident: bib46 article-title: Prognostic relevance of genetic alterations in diffuse lower-grade gliomas publication-title: Neuro Oncol. – reference: Natsumeda, M., et al. Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features. – volume: 22 start-page: 936 year: 2020 end-page: 943 ident: bib97 article-title: “Real world” use of a highly reliable imaging sign: “T2-FLAIR mismatch” for identification of IDH mutant astrocytomas publication-title: Neuro Oncol. – volume: 1 start-page: 1 year: 2019 end-page: 11 ident: bib36 article-title: Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks publication-title: Neurooncol. Adv. – volume: 34 start-page: 139 year: 2017 end-page: 140 ident: bib2 article-title: Updated 2016 WHO classification of tumors of the CNS: turning the corner where molecule meets pathology publication-title: Brain Tumor Pathol. – reference: WHO Classification of Tumours Editorial Board. – reference: Louis, D. N., Ohgaki H., Wiestler O. D., Cavenee W. K. – volume: 37 start-page: 33 year: 2020 end-page: 40 ident: bib4 article-title: Correlation between IDH, ATRX, and TERT promoter mutations in glioma publication-title: Brain Tumor Pathol. – reference: . – volume: 74 start-page: 442 year: 2015 end-page: 452 ident: bib43 article-title: CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas publication-title: J. Neuropathol. Exp. Neurol. – volume: 129 start-page: 585 year: 2015 end-page: 596 ident: bib32 article-title: IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas publication-title: Acta Neuropathol. – volume: 34 start-page: 141 year: 2017 end-page: 148 ident: bib18 article-title: Modified rapid immunohistochemical staining for intraoperative diagnosis of malignant brain tumors publication-title: Brain Tumor Pathol. – volume: 20 start-page: 608 year: 2018 end-page: 620 ident: bib74 article-title: Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications publication-title: Neuro Oncol. – reference: Kleihues, P., Burger, P. C., Scheithauer, B. W. – volume: 18 start-page: 553 year: 2010 end-page: 567 ident: bib29 article-title: Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation publication-title: Cancer Cell – volume: 21 start-page: 819 year: 2019 end-page: 821 ident: bib42 article-title: Targeted copy number analysis outperforms histological grading in predicting patient survival for WHO grade II/III IDH-mutant astrocytomas publication-title: Neuro Oncol. – volume: 34 start-page: 1542 year: 2013 end-page: 1549 ident: bib95 article-title: Differentiation between oligodendroglioma genotypes using dynamic susceptibility contrast perfusion-weighted imaging and proton MR spectroscopy publication-title: Am. J. Neuroradiol. – volume: 33 start-page: 245 year: 2020 end-page: 254 ident: bib104 article-title: MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma publication-title: Mod. Pathol. – volume: 136 start-page: 153 year: 2018 end-page: 166 ident: bib44 article-title: Novel, improved grading system(s) for IDH-mutant astrocytic gliomas publication-title: Acta Neuropathol. – volume: 133 start-page: 1 year: 2017 end-page: 3 ident: bib23 article-title: Announcing cIMPACT-NOW: the consortium to inform molecular and practical approaches to CNS tumor taxonomy publication-title: Acta Neuropathol. – volume: 58 start-page: 46 year: 1999 end-page: 53 ident: bib21 article-title: Cellular proliferation in pilocytic and diffuse astrocytomas publication-title: J. Neuropathol. Exp. Neurol. – reference: Ammendola, S., et al. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology. – volume: 131 start-page: 234 year: 2007 end-page: 241 ident: bib16 article-title: New immunohistochemical markers in the evaluation of central nervous system tumors: a review of 7 selected adult and pediatric brain tumors publication-title: Arch. Pathol. Lab. Med. – volume: 101 start-page: 412 year: 2021 end-page: 422 ident: bib107 article-title: Artificial intelligence and computational pathology publication-title: Lab Investig. – volume: 25 start-page: 527 year: 2012 end-page: 529 ident: bib9 article-title: James Watson Kernohan (1896-198): frontiers in neuropathology publication-title: Clin. Anat. – volume: 45 start-page: 108 year: 2019 end-page: 118 ident: bib37 article-title: Integrated molecular characterization of IDH-mutant glioblastomas publication-title: Neuropathol. Appl. Neurobiol. – volume: 23 start-page: 565 year: 2013 end-page: 573 ident: bib47 article-title: PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma publication-title: Brain Pathol. – volume: 69 start-page: 255 year: 2016 end-page: 259 ident: bib22 article-title: The importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 index publication-title: J. Clin. Pathol. – volume: 129 start-page: 679 year: 2015 end-page: 693 ident: bib48 article-title: Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups publication-title: Acta Neuropathol. – volume: 13 start-page: 707 year: 2012 end-page: 715 ident: bib71 article-title: Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial publication-title: Lancet Oncol. – volume: 321 start-page: 1807 year: 2008 end-page: 1812 ident: bib25 article-title: An integrated genomic analysis of human glioblastoma multiforme publication-title: Science – volume: 13 start-page: 102 year: 2021 end-page: 113 ident: bib40 article-title: DNA methylation profiling for molecular classification of adult diffuse lower-grade gliomas publication-title: Clin Epigenet. – volume: 35 start-page: 148 year: 2018 end-page: 158 ident: bib88 article-title: Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas publication-title: Brain Tumor Pathol. – volume: 136 start-page: 181 year: 2018 end-page: 210 ident: bib53 article-title: Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience publication-title: Acta Neuropathol. – volume: 30 start-page: 253 year: 2013 end-page: 261 ident: bib60 article-title: Controversies over the diagnosis of oligodendroglioma: a report from the satellite workshop at the 4th international symposium of brain tumor pathology, Nagoya Congress Center, May 23, 2012 publication-title: Brain Tumor Pathol. – volume: 134 start-page: 517 year: 2017 end-page: 520 ident: bib6 article-title: Grading of diffuse astrocytic gliomas: Broders, Kernohan, Zulch, the WHO… and Shakespeare publication-title: Acta Neuropathol. – volume: 19 start-page: 551 year: 2009 end-page: 564 ident: bib10 article-title: Development of the WHO classification of tumors of the central nervous system: a historical perspective publication-title: Brain Pathol. – volume: 6 start-page: 43 year: 2011 end-page: 51 ident: bib17 article-title: Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIalpha in human anaplastic astrocytomas–an immunohistochemical study publication-title: Diagn. Pathol. – reference: (World Health Organization, Geneva, 1979). – volume: 114 start-page: 97 year: 2007 end-page: 109 ident: bib14 article-title: The 2007 WHO classification of tumours of the central nervous system publication-title: Acta Neuropathol. – volume: 36 start-page: 56 year: 2019 end-page: 62 ident: bib86 article-title: Practical procedures for the integrated diagnosis of astrocytic and oligodendroglial tumors publication-title: Brain Tumor Pathol. – volume: 62 start-page: 2152 year: 1988 end-page: 2165 ident: bib13 article-title: Grading of astrocytomas. A simple and reproducible method publication-title: Cancer – volume: 26 start-page: 551 year: 2016 end-page: 554 ident: bib84 article-title: A global view on the availability of methods and information in the neuropathological diagnostics of CNS tumors: results of an international survey among neuropathological units publication-title: Brain Pathol. – reference: FigueroaMELeukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiationCancer Cell2010185535671:CAS:528:DC%2BC3cXhsFGhsbvJ21130701410584510.1016/j.ccr.2010.11.015 – reference: FriedmanHSDNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant gliomaJ. Clin. Oncol.199816385138571:CAS:528:DyaK1MXos1Si985003010.1200/JCO.1998.16.12.3851 – reference: WickWTemozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trialLancet Oncol.2012137077151:CAS:528:DC%2BC38XhtVShtrjK2257879310.1016/S1470-2045(12)70164-X – reference: AdachiJ-iDroplet digital PCR assay for detecting TERT promoter mutations in patients with gliomaBrain Tumor Pathol.2021382012091:CAS:528:DC%2BB3MXhvF2qsrbN3412811110.1007/s10014-021-00403-4 – reference: AndreiuoloFMazeraudAChretienFPietschTA global view on the availability of methods and information in the neuropathological diagnostics of CNS tumors: results of an international survey among neuropathological unitsBrain Pathol.20162655155427062283802891510.1111/bpa.12383 – reference: RichardsonTEHatanpaaKJWalkerJMMolecular characterization of “True” low-grade IDH-wild-type astrocytomasJ. Neuropathol. Exp. Neurol.2021804314351:CAS:528:DC%2BB3MXitVOrsbvL3382925910.1093/jnen/nlab023 – reference: Perry, A., Brat D. J. Practical Surgical Neuropathology (Elsevier, Philadelphia, 2018). – reference: ShirahataMNovel, improved grading system(s) for IDH-mutant astrocytic gliomasActa Neuropathol.20181361531661:CAS:528:DC%2BC1cXos1Sgsb4%3D2968725810.1007/s00401-018-1849-4 – reference: WooHYGlioblastomas harboring gene fusions detected by next-generation sequencingBrain Tumor Pathol.2020371361441:CAS:528:DC%2BB3cXhsFykt7vL3276153310.1007/s10014-020-00377-9 – reference: FilipskiKLack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomasActa Neuropathol.201913833133431065834666049810.1007/s00401-019-02025-9 – reference: YamamichiAImmunohistochemical ATRX expression is not a surrogate for 1p19q codeletionBrain Tumor Pathol.2018351061131:CAS:528:DC%2BC1cXltVKgu7w%3D2955088010.1007/s10014-018-0312-5 – reference: CohenADNA copy number analysis of grade II–III and grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation statusActa Neuropathol. Commun.20153344626091668447435110.1186/s40478-015-0213-31:CAS:528:DC%2BC28XpsV2mtLg%3D – reference: GianniniCCellular proliferation in pilocytic and diffuse astrocytomasJ. Neuropathol. Exp. Neurol.19995846531:STN:280:DyaK1M7jvF2isQ%3D%3D1006831310.1097/00005072-199901000-00006 – reference: BinderHDNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and developmentActa Neuropathol. Commun.20197591:STN:280:DC%2BB3M%2Fpt1GnsQ%3D%3D31023364648257310.1186/s40478-019-0704-8 – reference: StichelDDistribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastomaActa Neuropathol.20181367938033018712110.1007/s00401-018-1905-0 – reference: Kleihues, P., Cavenee, W. K. Pathology and Genetics of Tumors of the Nervous System (World Health Organization classification of tumors, IARC Press, Lyon, France, 2000). – reference: OstromQTCBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017Neuro Oncol.202022iv1iv9633123732759624710.1093/neuonc/noaa200 – reference: SatomiKUtility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytomaMod. Pathol.2021346887001:CAS:528:DC%2BB3cXitFWjurfF3307792410.1038/s41379-020-00701-w – reference: OhbaSKuwaharaKYamadaSAbeMHiroseYCorrelation between IDH, ATRX, and TERT promoter mutations in gliomaBrain Tumor Pathol.20203733403222725910.1007/s10014-020-00360-4 – reference: BratDJVerhaakRGAldapeKDYungWKSalamaSRComprehensive, integrative genomic analysis of diffuse lower-grade gliomasN. Engl. J. Med.2015372248124981:CAS:528:DC%2BC2MXhtFyrsbrK2606175110.1056/NEJMoa1402121 – reference: WickWMGMT testing–the challenges for biomarker-based glioma treatmentNat. Rev. Neurol.2014103723851:CAS:528:DC%2BC2cXpslChsbY%3D2491251210.1038/nrneurol.2014.100 – reference: YokogamiKImpact of PCR-based molecular analysis in daily diagnosis for the patient with gliomasBrain Tumor Pathol.2018351411471:CAS:528:DC%2BC1cXht1ekur3M2993148510.1007/s10014-018-0322-3 – reference: CeccarelliMMolecular profiling reveals biologically discrete subsets and pathways of progression in diffuse gliomaCell20161645505631:CAS:528:DC%2BC28Xhs12ls7o%3D26824661475411010.1016/j.cell.2015.12.028 – reference: WrightJRAlbertCJrBroders’ paradigm shifts involving the prognostication and definition of cancerArch. Pathol. Lab. Med.2012136143714462310659010.5858/arpa.2011-0567-HP – reference: OlarAIDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomasActa Neuropathol.20151295855961:CAS:528:DC%2BC2MXjs1Glu7k%3D25701198436918910.1007/s00401-015-1398-z – reference: MikiSHighly sensitive detection of TERT promoter mutations in recurrent glioblastomas using digital PCRBrain Tumor Pathol.2020371541581:CAS:528:DC%2BB3cXhsFegt73L3274962410.1007/s10014-020-00375-x – reference: BroenMPGThe T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation studyNeuro Oncol.201820139313991:CAS:528:DC%2BC1MXhtlKntLbI29590424612036310.1093/neuonc/noy048 – reference: HalaniSHMulti-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathwaysNPJ Precis. Oncol.20182243330417117621950510.1038/s41698-018-0067-9 – reference: SuzukiAModified rapid immunohistochemical staining for intraoperative diagnosis of malignant brain tumorsBrain Tumor Pathol.2017341411481:CAS:528:DC%2BC2sXhtlKnu77J2882309810.1007/s10014-017-0293-9 – reference: CapperDPractical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experienceActa Neuropathol.20181361812101:CAS:528:DC%2BC1cXht1yks7vL29967940606079010.1007/s00401-018-1879-y – reference: JainR“Real world” use of a highly reliable imaging sign: “T2-FLAIR mismatch” for identification of IDH mutant astrocytomasNeuro Oncol.2020229369431:CAS:528:DC%2BB3cXisVyqtrzN32064507733989610.1093/neuonc/noaa041 – reference: FukaiJMolecular characteristics and clinical outcomes of elderly patients with IDH-wild-type glioblastomas: comparative study of older and younger cases in Kansai Network cohortBrain Tumor Pathol.20203750591:CAS:528:DC%2BB3cXos1Gitbs%3D3236194110.1007/s10014-020-00363-1 – reference: Natsumeda, M., et al. Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features. Brain Tumor Pathol. (2021) – reference: RouxAPrognostic relevance of adding MRI data to WHO 2016 and cIMPACT-NOW updates for diffuse astrocytic tumors in adults. Working toward the extended use of MRI data in integrated glioma diagnosisBrain Pathol.202131e129291:CAS:528:DC%2BB3MXhs1SksrvP33336392841211510.1111/bpa.12929 – reference: TesileanuCMSSurvival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteriaNeuro Oncol.2020225155231:CAS:528:DC%2BB3cXitV2isb7N3163741410.1093/neuonc/noz200 – reference: Ammendola, S., et al. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology. Virchows Arch. https://doi.org/10.1007/s00428-021-03134-1 (2021). – reference: AppayRCDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomasNeuro Oncol.201921151915281:CAS:528:DC%2BB3cXhvFers7%2FI31832685714556110.1093/neuonc/noz126.000 – reference: ReisGFCDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomasJ. Neuropathol. Exp. Neurol.2015744424521:CAS:528:DC%2BC2MXmslWisr8%3D2585369410.1097/NEN.0000000000000188 – reference: LouisDNThe 2007 WHO classification of tumours of the central nervous systemActa Neuropathol.20071149710917618441192916510.1007/s00401-007-0243-4 – reference: CiminoPJMultidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discoveryActa Neuropathol. Commun.20175395328532485543911710.1186/s40478-017-0443-71:CAS:528:DC%2BC1cXhvFaqtLjN – reference: KorshunovAIntegrated molecular characterization of IDH-mutant glioblastomasNeuropathol. Appl. Neurobiol.2019451081181:CAS:528:DC%2BC1MXjtFKmtr4%3D3032616310.1111/nan.12523 – reference: KillelaPJTERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewalProc. Natl Acad. Sci. USA2013110602160261:CAS:528:DC%2BC3sXnsFKksbc%3D23530248362533110.1073/pnas.1303607110 – reference: ChapelDBMTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesotheliomaMod. Pathol.2020332452541:CAS:528:DC%2BC1MXht1Kqt7nJ3123112710.1038/s41379-019-0310-0 – reference: LatyshevaADynamic susceptibility contrast and diffusion MR imaging identify oligodendroglioma as defined by the 2016 WHO classification for brain tumors: histogram analysis approachNeuroradiology2019615455553071213910.1007/s00234-019-02173-5 – reference: GianniniCAnaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402Brain Pathol.20081836036918371182809553510.1111/j.1750-3639.2008.00129.x – reference: CiminoPJHollandECTargeted copy number analysis outperforms histological grading in predicting patient survival for WHO grade II/III IDH-mutant astrocytomasNeuro Oncol.20192181982130918961655684110.1093/neuonc/noz052 – reference: KomoriTUpdated 2016 WHO classification of tumors of the CNS: turning the corner where molecule meets pathologyBrain Tumor Pathol.2017341391402884040310.1007/s10014-017-0299-3 – reference: LouisDNcIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and gradingBrain Pathol.20203084485632307792801815210.1111/bpa.12832 – reference: NoushmehrHIdentification of a CpG island methylator phenotype that defines a distinct subgroup of gliomaCancer Cell2010175105221:CAS:528:DC%2BC3cXmslKqsr0%3D20399149287268410.1016/j.ccr.2010.03.017 – reference: AokiKNatsumeAOverview of DNA methylation in adult diffuse gliomasBrain Tumor Pathol.20193684911:CAS:528:DC%2BB3cXlsFOjtr4%3D3093770310.1007/s10014-019-00339-w – reference: KomoriTUpdating the grading criteria for adult diffuse gliomas: beyond the WHO2016CNS classificationBrain Tumor Pathol.202037141:CAS:528:DC%2BB3cXjsVOltLY%3D3206066010.1007/s10014-020-00358-y – reference: Eckel-PassowJEGlioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumorsN. Engl. J. Med.2015372249925081:CAS:528:DC%2BC2MXhtFyrsbvO26061753448970410.1056/NEJMoa1407279 – reference: EtienneDJames Watson Kernohan (1896-198): frontiers in neuropathologyClin. Anat.2012255275292233160110.1002/ca.22000 – reference: Ferreyra VegaSDNA methylation profiling for molecular classification of adult diffuse lower-grade gliomasClin Epigenet.2021131021131:CAS:528:DC%2BB3MXhtlSrs73P10.1186/s13148-021-01085-7 – reference: KomoriTControversies over the diagnosis of oligodendroglioma: a report from the satellite workshop at the 4th international symposium of brain tumor pathology, Nagoya Congress Center, May 23, 2012Brain Tumor Pathol.2013302532612410079410.1007/s10014-013-0165-x – reference: HabberstadAHGulatiSTorpSHEvaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIalpha in human anaplastic astrocytomas–an immunohistochemical studyDiagn. Pathol.20116435121609421312781510.1186/1746-1596-6-43 – reference: ScheithauerBWDevelopment of the WHO classification of tumors of the central nervous system: a historical perspectiveBrain Pathol.2009195515641877152610.1111/j.1750-3639.2008.00192.x – reference: TateishiKNakamuraTYamamotoTMolecular genetics and therapeutic targets of pediatric low-grade gliomasBrain Tumor Pathol.20193674833092911310.1007/s10014-019-00340-3 – reference: DuregonEKi-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomasOncotarget201672190219810.18632/oncotarget.8498 – reference: Louis, D. N., Ohgaki H., Wiestler O. D., Cavenee W. K. WHO Classification of Tumours of the Central Nervous System (International Agency for Research on Cancer, Lyon, 2016). – reference: Daumas-DuportCScheithauerBO’FallonJKellyPGrading of astrocytomas. A simple and reproducible methodCancer198862215221651:STN:280:DyaL1M%2FivVSqtg%3D%3D317992810.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T – reference: LouisDNThe 2021 WHO classification of tumors of the central nervous system: a summaryNeuro Oncol.202123123112511:CAS:528:DC%2BB3MXisFSht73J3418507610.1093/neuonc/noab106 – reference: MaltaTMGlioma CpG island methylator phenotype (G-CIMP): biological and clinical implicationsNeuro Oncol.2018206086201:CAS:528:DC%2BC1MXps1OgtbY%3D2903650010.1093/neuonc/nox183 – reference: LouisDNThe 2016 World Health Organization classification of tumors of the central nervous system: a summaryActa Neuropathol.20161318038202715793110.1007/s00401-016-1545-1 – reference: LouisDNcIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutantActa Neuropathol.20181356396422949781910.1007/s00401-018-1826-y – reference: YangRRIDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterationsBrain Pathol.20193054155331733156801813810.1111/bpa.128011:CAS:528:DC%2BB3cXovFGjtb8%3D – reference: LouisDNAnnouncing cIMPACT-NOW: the consortium to inform molecular and practical approaches to CNS tumor taxonomyActa Neuropathol.2017133132790980910.1007/s00401-016-1646-x – reference: MirchiaKEstablishing a prognostic threshold for total copy number variation within adult IDH-mutant grade II/III astrocytomasActa Neuropathol. Commun.2019712112431349875666095510.1186/s40478-019-0778-3 – reference: LouisDNInternational Society Of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and gradingBrain Pathol.20142442943524990071802949010.1111/bpa.12171 – reference: LabrecheKTCF12 is mutated in anaplastic oligodendrogliomaNat. Commun.20156720772161:CAS:528:DC%2BC2MXhtF2ktrnI2606820110.1038/ncomms8207 – reference: WellerMMolecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groupsActa Neuropathol.20151296796931:CAS:528:DC%2BC2MXltVWlsLY%3D2578374710.1007/s00401-015-1409-0 – reference: RajeswarieRTRaoSNandeeshBNYashaTCSantoshVA simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-upJ. Clin. Pathol.2018713233291:CAS:528:DC%2BC1cXitlKgt7fK2880134710.1136/jclinpath-2017-204638 – reference: YodaRAMitotic index thresholds do not predict clinical outcome for IDH-mutant astrocytomaJ. Neuropathol. Exp. Neurol.201978100210103152904810.1093/jnen/nlz082 – reference: LiKKIdentification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risksNeurooncol. Adv.20191111 – reference: LouisDNData sets for the reporting of tumors of the central nervous system: recommendations from the International Collaboration on Cancer ReportingArch. Pathol. Lab. Med.20201441962063121934410.5858/arpa.2018-0565-OA – reference: KomoriTThe molecular framework of pediatric-type diffuse gliomas: shifting toward the revision of the WHO classification of tumors of the central nervous systemBrain Tumor Pathol.202138133339847210.1007/s10014-020-00392-w – reference: YamauchiTRadiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomasBrain Tumor Pathol.2018351481581:CAS:528:DC%2BC1cXhtFKgsbjF2992297410.1007/s10014-018-0321-4 – reference: FellahSMultimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis?Am. J. Neuroradiol.201334132613331:STN:280:DC%2BC3s7pvVansQ%3D%3D23221948805148710.3174/ajnr.A3352 – reference: LouisDNcIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC)Acta Neuropathol.20181354814842937231810.1007/s00401-018-1808-0 – reference: LouisDNvon DeimlingAGrading of diffuse astrocytic gliomas: Broders, Kernohan, Zulch, the WHO… and ShakespeareActa Neuropathol.20171345175202880169310.1007/s00401-017-1765-z – reference: CapperDDNA methylation-based classification of central nervous system tumoursNature20185554694741:CAS:528:DC%2BC1cXksFegu70%3D29539639609321810.1038/nature26000 – reference: GianniniCOligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and gradingJ. Neuropathol. Exp. Neurol.2001602482621:STN:280:DC%2BD3M7osVOitA%3D%3D1124520910.1093/jnen/60.3.248 – reference: JohnsonDRGenetically defined oligodendroglioma is characterized by indistinct tumor borders at MRIAm. J. Neuroradiol.2017386786841:STN:280:DC%2BC1c7ps1Kltw%3D%3D28126746796025410.3174/ajnr.A5070 – reference: PhillipsJJPDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastomaBrain Pathol.2013235655731:CAS:528:DC%2BC3sXhs12mt7rI23438035371557010.1111/bpa.12043 – reference: ChawlaSDifferentiation between oligodendroglioma genotypes using dynamic susceptibility contrast perfusion-weighted imaging and proton MR spectroscopyAm. J. Neuroradiol.201334154215491:STN:280:DC%2BC3szksVKguw%3D%3D23370479805145510.3174/ajnr.A3384 – reference: ParsonsDWAn integrated genomic analysis of human glioblastoma multiformeScience2008321180718121:CAS:528:DC%2BD1cXhtFCrtLrE18772396282038910.1126/science.1164382 – reference: KuwaharaKClinical, histopathological, and molecular analyses of IDH-wild-type WHO grade II–III gliomas to establish genetic predictors of poor prognosisBrain Tumor Pathol.2019361351433132499910.1007/s10014-019-00348-9 – reference: EllisonDWcIMPACT-NOW update 7: advancing the molecular classification of ependymal tumorsBrain Pathol.202030863866325023058018155 – reference: HegiMEMGMT gene silencing and benefit from temozolomide in glioblastomaN. Engl. J. Med.200535299710031:CAS:528:DC%2BD2MXit1Wktro%3D1575801010.1056/NEJMoa043331 – reference: AritaHA combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomasActa Neuropathol. Commun.20164799327503138497771510.1186/s40478-016-0351-21:CAS:528:DC%2BC2sXhs1GhsLrE – reference: SaitoTCalcification on CT is a simple and valuable preoperative indicator of 1p/19q loss of heterozygosity in supratentorial brain tumors that are suspected grade II and III gliomasBrain Tumor Pathol.2016331751821:CAS:528:DC%2BC28Xit12ksLg%3D2684937310.1007/s10014-016-0249-5 – reference: ArimaNThe importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 indexJ. Clin. Pathol.2016692552591:CAS:528:DC%2BC28XhtlWnurjK2642076710.1136/jclinpath-2015-203174 – reference: GianniniCGiangasperoFTERT promoter mutation: is it enough to call a WHO grade II astrocytoma IDH wild-type glioblastoma?Neuro Oncol.20212386586633660766816880610.1093/neuonc/noab052 – reference: ReussDEAdult IDH wild type astrocytomas biologically and clinically resolve into other tumor entitiesActa Neuropathol.20151304074171:CAS:528:DC%2BC2MXhtVOhsb7K2608790410.1007/s00401-015-1454-8 – reference: SmitsMImaging of oligodendrogliomaBr. J. Radiol.2016892015085726849038484621310.1259/bjr.20150857 – reference: AokiKPrognostic relevance of genetic alterations in diffuse lower-grade gliomasNeuro Oncol.20182066771:CAS:528:DC%2BC1MXps1Ogtr0%3D2901683910.1093/neuonc/nox132 – reference: Kleihues, P., Burger, P. C., Scheithauer, B. W. Histological Typing of Tumours of the Central Nevous System (Springer-Verlag, Berlin, 1993). – reference: CuiMZhangDYArtificial intelligence and computational pathologyLab Investig.20211014124223345472410.1038/s41374-020-00514-0 – reference: EllisonDWcIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF(V600E) mutationActa Neuropathol.20191376836871:CAS:528:DC%2BC1MXmslKisrw%3D3084834710.1007/s00401-019-01987-0 – reference: Zülch, K. J. Histological Typing of Tumours of the Central Nervous System (World Health Organization, Geneva, 1979). – reference: TakeiHBhattacharjeeMBRiveraADancerYPowellSZNew immunohistochemical markers in the evaluation of central nervous system tumors: a review of 7 selected adult and pediatric brain tumorsArch. Pathol. Lab. Med.20071312342411:CAS:528:DC%2BD2sXisFylsrk%3D1728410810.5858/2007-131-234-NIMITE – reference: BerzeroGIDH-wild-type lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratificationNeuro Oncol.2021239559663317394110.1093/neuonc/noaa258 – reference: FujimotoKTERT promoter mutation status is necessary and sufficient to diagnose IDH-wild-type diffuse astrocytic glioma with molecular features of glioblastomaActa Neuropathol.20211423233381:CAS:528:DC%2BB3MXhsFOgt7rK3414810510.1007/s00401-021-02337-9 – reference: SoJMamatjanYZadehGAldapeKMoraesFYTranscription factor networks of oligodendrogliomas treated with adjuvant radiotherapy or observation inform prognosisNeuro Oncol.2021237958023336775310.1093/neuonc/noaa300 – reference: SonodaYPractical procedures for the integrated diagnosis of astrocytic and oligodendroglial tumorsBrain Tumor Pathol.20193656621:CAS:528:DC%2BC1MXhtVCjtbjP3084771110.1007/s10014-019-00337-y – reference: WHO Classification of Tumours Editorial Board. World Health Organization Classification of Tumours of the Central Nervous System (International Agency for Research on Cancer, Lyon, 2021) in press. – reference: AkagiYReclassification of 400 consecutive glioma cases based on the revised 2016WHO classificationBrain Tumor Pathol.20183581891:CAS:528:DC%2BC1cXlslSlsr8%3D2956916310.1007/s10014-018-0313-4 – volume: 71 start-page: 323 year: 2018 ident: 10.1038/s41374-021-00667-6_bib87 article-title: A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up publication-title: J. Clin. Pathol. doi: 10.1136/jclinpath-2017-204638 – ident: 10.1038/s41374-021-00667-6_bib89 doi: 10.1007/s10014-021-00407-0 – volume: 3 start-page: 34 year: 2015 ident: 10.1038/s41374-021-00667-6_bib78 article-title: DNA copy number analysis of grade II–III and grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status publication-title: Acta Neuropathol. Commun. doi: 10.1186/s40478-015-0213-3 – volume: 21 start-page: 1519 year: 2019 ident: 10.1038/s41374-021-00667-6_bib45 article-title: CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas publication-title: Neuro Oncol. doi: 10.1093/neuonc/noz126.000 – volume: 23 start-page: 795 year: 2021 ident: 10.1038/s41374-021-00667-6_bib63 article-title: Transcription factor networks of oligodendrogliomas treated with adjuvant radiotherapy or observation inform prognosis publication-title: Neuro Oncol. doi: 10.1093/neuonc/noaa300 – volume: 26 start-page: 551 year: 2016 ident: 10.1038/s41374-021-00667-6_bib84 article-title: A global view on the availability of methods and information in the neuropathological diagnostics of CNS tumors: results of an international survey among neuropathological units publication-title: Brain Pathol. doi: 10.1111/bpa.12383 – volume: 13 start-page: 707 year: 2012 ident: 10.1038/s41374-021-00667-6_bib71 article-title: Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(12)70164-X – volume: 89 start-page: 20150857 year: 2016 ident: 10.1038/s41374-021-00667-6_bib92 article-title: Imaging of oligodendroglioma publication-title: Br. J. Radiol. doi: 10.1259/bjr.20150857 – volume: 18 start-page: 360 year: 2008 ident: 10.1038/s41374-021-00667-6_bib58 article-title: Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402 publication-title: Brain Pathol. doi: 10.1111/j.1750-3639.2008.00129.x – volume: 13 start-page: 102 year: 2021 ident: 10.1038/s41374-021-00667-6_bib40 article-title: DNA methylation profiling for molecular classification of adult diffuse lower-grade gliomas publication-title: Clin Epigenet. doi: 10.1186/s13148-021-01085-7 – volume: 36 start-page: 84 year: 2019 ident: 10.1038/s41374-021-00667-6_bib75 article-title: Overview of DNA methylation in adult diffuse gliomas publication-title: Brain Tumor Pathol. doi: 10.1007/s10014-019-00339-w – volume: 137 start-page: 683 year: 2019 ident: 10.1038/s41374-021-00667-6_bib77 article-title: cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF(V600E) mutation publication-title: Acta Neuropathol. doi: 10.1007/s00401-019-01987-0 – volume: 101 start-page: 412 year: 2021 ident: 10.1038/s41374-021-00667-6_bib107 article-title: Artificial intelligence and computational pathology publication-title: Lab Investig. doi: 10.1038/s41374-020-00514-0 – volume: 45 start-page: 108 year: 2019 ident: 10.1038/s41374-021-00667-6_bib37 article-title: Integrated molecular characterization of IDH-mutant glioblastomas publication-title: Neuropathol. Appl. Neurobiol. doi: 10.1111/nan.12523 – volume: 129 start-page: 679 year: 2015 ident: 10.1038/s41374-021-00667-6_bib48 article-title: Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups publication-title: Acta Neuropathol. doi: 10.1007/s00401-015-1409-0 – volume: 17 start-page: 510 year: 2010 ident: 10.1038/s41374-021-00667-6_bib73 article-title: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma publication-title: Cancer Cell doi: 10.1016/j.ccr.2010.03.017 – volume: 38 start-page: 201 year: 2021 ident: 10.1038/s41374-021-00667-6_bib80 article-title: Droplet digital PCR assay for detecting TERT promoter mutations in patients with glioma publication-title: Brain Tumor Pathol. doi: 10.1007/s10014-021-00403-4 – volume: 134 start-page: 517 year: 2017 ident: 10.1038/s41374-021-00667-6_bib6 article-title: Grading of diffuse astrocytic gliomas: Broders, Kernohan, Zulch, the WHO… and Shakespeare publication-title: Acta Neuropathol. doi: 10.1007/s00401-017-1765-z – volume: 22 start-page: iv1 year: 2020 ident: 10.1038/s41374-021-00667-6_bib64 article-title: CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017 publication-title: Neuro Oncol. doi: 10.1093/neuonc/noaa200 – volume: 30 start-page: 844 year: 2020 ident: 10.1038/s41374-021-00667-6_bib24 article-title: cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading publication-title: Brain Pathol. doi: 10.1111/bpa.12832 – volume: 33 start-page: 175 year: 2016 ident: 10.1038/s41374-021-00667-6_bib98 article-title: Calcification on CT is a simple and valuable preoperative indicator of 1p/19q loss of heterozygosity in supratentorial brain tumors that are suspected grade II and III gliomas publication-title: Brain Tumor Pathol. doi: 10.1007/s10014-016-0249-5 – volume: 4 start-page: 79 year: 2016 ident: 10.1038/s41374-021-00667-6_bib28 article-title: A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas publication-title: Acta Neuropathol. Commun. doi: 10.1186/s40478-016-0351-2 – volume: 6 start-page: 7207 year: 2015 ident: 10.1038/s41374-021-00667-6_bib62 article-title: TCF12 is mutated in anaplastic oligodendroglioma publication-title: Nat. Commun. doi: 10.1038/ncomms8207 – volume: 34 start-page: 688 year: 2021 ident: 10.1038/s41374-021-00667-6_bib105 article-title: Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma publication-title: Mod. Pathol. doi: 10.1038/s41379-020-00701-w – volume: 30 start-page: 863 year: 2020 ident: 10.1038/s41374-021-00667-6_bib67 article-title: cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors publication-title: Brain Pathol. doi: 10.1111/bpa.12866 – volume: 352 start-page: 997 year: 2005 ident: 10.1038/s41374-021-00667-6_bib68 article-title: MGMT gene silencing and benefit from temozolomide in glioblastoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa043331 – volume: 69 start-page: 255 year: 2016 ident: 10.1038/s41374-021-00667-6_bib22 article-title: The importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 index publication-title: J. Clin. Pathol. doi: 10.1136/jclinpath-2015-203174 – volume: 61 start-page: 545 year: 2019 ident: 10.1038/s41374-021-00667-6_bib93 article-title: Dynamic susceptibility contrast and diffusion MR imaging identify oligodendroglioma as defined by the 2016 WHO classification for brain tumors: histogram analysis approach publication-title: Neuroradiology doi: 10.1007/s00234-019-02173-5 – volume: 144 start-page: 196 year: 2020 ident: 10.1038/s41374-021-00667-6_bib83 article-title: Data sets for the reporting of tumors of the central nervous system: recommendations from the International Collaboration on Cancer Reporting publication-title: Arch. Pathol. Lab. Med. doi: 10.5858/arpa.2018-0565-OA – ident: 10.1038/s41374-021-00667-6_bib12 doi: 10.1007/978-3-642-84988-6 – volume: 34 start-page: 1542 year: 2013 ident: 10.1038/s41374-021-00667-6_bib95 article-title: Differentiation between oligodendroglioma genotypes using dynamic susceptibility contrast perfusion-weighted imaging and proton MR spectroscopy publication-title: Am. J. Neuroradiol. doi: 10.3174/ajnr.A3384 – volume: 21 start-page: 819 year: 2019 ident: 10.1038/s41374-021-00667-6_bib42 article-title: Targeted copy number analysis outperforms histological grading in predicting patient survival for WHO grade II/III IDH-mutant astrocytomas publication-title: Neuro Oncol. doi: 10.1093/neuonc/noz052 – volume: 37 start-page: 1 year: 2020 ident: 10.1038/s41374-021-00667-6_bib5 article-title: Updating the grading criteria for adult diffuse gliomas: beyond the WHO2016CNS classification publication-title: Brain Tumor Pathol. doi: 10.1007/s10014-020-00358-y – ident: 10.1038/s41374-021-00667-6_bib99 doi: 10.1007/s00428-021-03134-1 – volume: 34 start-page: 139 year: 2017 ident: 10.1038/s41374-021-00667-6_bib2 article-title: Updated 2016 WHO classification of tumors of the CNS: turning the corner where molecule meets pathology publication-title: Brain Tumor Pathol. doi: 10.1007/s10014-017-0299-3 – volume: 78 start-page: 1002 year: 2019 ident: 10.1038/s41374-021-00667-6_bib33 article-title: Mitotic index thresholds do not predict clinical outcome for IDH-mutant astrocytoma publication-title: J. Neuropathol. Exp. Neurol. doi: 10.1093/jnen/nlz082 – ident: 10.1038/s41374-021-00667-6_bib15 – volume: 7 start-page: 121 year: 2019 ident: 10.1038/s41374-021-00667-6_bib79 article-title: Establishing a prognostic threshold for total copy number variation within adult IDH-mutant grade II/III astrocytomas publication-title: Acta Neuropathol. Commun. doi: 10.1186/s40478-019-0778-3 – volume: 37 start-page: 154 year: 2020 ident: 10.1038/s41374-021-00667-6_bib81 article-title: Highly sensitive detection of TERT promoter mutations in recurrent glioblastomas using digital PCR publication-title: Brain Tumor Pathol. doi: 10.1007/s10014-020-00375-x – volume: 135 start-page: 481 year: 2018 ident: 10.1038/s41374-021-00667-6_bib102 article-title: cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC) publication-title: Acta Neuropathol. doi: 10.1007/s00401-018-1808-0 – volume: 18 start-page: 553 year: 2010 ident: 10.1038/s41374-021-00667-6_bib29 article-title: Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation publication-title: Cancer Cell doi: 10.1016/j.ccr.2010.11.015 – volume: 164 start-page: 550 year: 2016 ident: 10.1038/s41374-021-00667-6_bib39 article-title: Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma publication-title: Cell doi: 10.1016/j.cell.2015.12.028 – volume: 19 start-page: 551 year: 2009 ident: 10.1038/s41374-021-00667-6_bib10 article-title: Development of the WHO classification of tumors of the central nervous system: a historical perspective publication-title: Brain Pathol. doi: 10.1111/j.1750-3639.2008.00192.x – volume: 555 start-page: 469 year: 2018 ident: 10.1038/s41374-021-00667-6_bib106 article-title: DNA methylation-based classification of central nervous system tumours publication-title: Nature doi: 10.1038/nature26000 – volume: 37 start-page: 50 year: 2020 ident: 10.1038/s41374-021-00667-6_bib72 article-title: Molecular characteristics and clinical outcomes of elderly patients with IDH-wild-type glioblastomas: comparative study of older and younger cases in Kansai Network cohort publication-title: Brain Tumor Pathol. doi: 10.1007/s10014-020-00363-1 – volume: 24 start-page: 429 year: 2014 ident: 10.1038/s41374-021-00667-6_bib85 article-title: International Society Of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading publication-title: Brain Pathol. doi: 10.1111/bpa.12171 – volume: 33 start-page: 245 year: 2020 ident: 10.1038/s41374-021-00667-6_bib104 article-title: MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma publication-title: Mod. Pathol. doi: 10.1038/s41379-019-0310-0 – volume: 136 start-page: 1437 year: 2012 ident: 10.1038/s41374-021-00667-6_bib8 article-title: Broders' paradigm shifts involving the prognostication and definition of cancer publication-title: Arch. Pathol. Lab. Med. doi: 10.5858/arpa.2011-0567-HP – volume: 23 start-page: 955 year: 2021 ident: 10.1038/s41374-021-00667-6_bib55 article-title: IDH-wild-type lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification publication-title: Neuro Oncol. doi: 10.1093/neuonc/noaa258 – volume: 7 start-page: 2190 year: 2016 ident: 10.1038/s41374-021-00667-6_bib19 article-title: Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas publication-title: Oncotarget doi: 10.18632/oncotarget.8498 – volume: 110 start-page: 6021 year: 2013 ident: 10.1038/s41374-021-00667-6_bib27 article-title: TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1303607110 – volume: 36 start-page: 135 year: 2019 ident: 10.1038/s41374-021-00667-6_bib51 article-title: Clinical, histopathological, and molecular analyses of IDH-wild-type WHO grade II–III gliomas to establish genetic predictors of poor prognosis publication-title: Brain Tumor Pathol. doi: 10.1007/s10014-019-00348-9 – volume: 30 start-page: 253 year: 2013 ident: 10.1038/s41374-021-00667-6_bib60 article-title: Controversies over the diagnosis of oligodendroglioma: a report from the satellite workshop at the 4th international symposium of brain tumor pathology, Nagoya Congress Center, May 23, 2012 publication-title: Brain Tumor Pathol. doi: 10.1007/s10014-013-0165-x – volume: 130 start-page: 407 year: 2015 ident: 10.1038/s41374-021-00667-6_bib52 article-title: Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities publication-title: Acta Neuropathol. doi: 10.1007/s00401-015-1454-8 – volume: 38 start-page: 678 year: 2017 ident: 10.1038/s41374-021-00667-6_bib91 article-title: Genetically defined oligodendroglioma is characterized by indistinct tumor borders at MRI publication-title: Am. J. Neuroradiol. doi: 10.3174/ajnr.A5070 – volume: 372 start-page: 2481 year: 2015 ident: 10.1038/s41374-021-00667-6_bib31 article-title: Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1402121 – volume: 23 start-page: 1231 year: 2021 ident: 10.1038/s41374-021-00667-6_bib34 article-title: The 2021 WHO classification of tumors of the central nervous system: a summary publication-title: Neuro Oncol. doi: 10.1093/neuonc/noab106 – volume: 25 start-page: 527 year: 2012 ident: 10.1038/s41374-021-00667-6_bib9 article-title: James Watson Kernohan (1896-198): frontiers in neuropathology publication-title: Clin. Anat. doi: 10.1002/ca.22000 – volume: 136 start-page: 793 year: 2018 ident: 10.1038/s41374-021-00667-6_bib49 article-title: Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma publication-title: Acta Neuropathol. doi: 10.1007/s00401-018-1905-0 – volume: 135 start-page: 639 year: 2018 ident: 10.1038/s41374-021-00667-6_bib103 article-title: cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant publication-title: Acta Neuropathol. doi: 10.1007/s00401-018-1826-y – volume: 58 start-page: 46 year: 1999 ident: 10.1038/s41374-021-00667-6_bib21 article-title: Cellular proliferation in pilocytic and diffuse astrocytomas publication-title: J. Neuropathol. Exp. Neurol. doi: 10.1097/00005072-199901000-00006 – ident: 10.1038/s41374-021-00667-6_bib20 – volume: 35 start-page: 81 year: 2018 ident: 10.1038/s41374-021-00667-6_bib3 article-title: Reclassification of 400 consecutive glioma cases based on the revised 2016WHO classification publication-title: Brain Tumor Pathol. doi: 10.1007/s10014-018-0313-4 – volume: 1 start-page: 1 year: 2019 ident: 10.1038/s41374-021-00667-6_bib36 article-title: Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks publication-title: Neurooncol. Adv. – volume: 10 start-page: 372 year: 2014 ident: 10.1038/s41374-021-00667-6_bib69 article-title: MGMT testing–the challenges for biomarker-based glioma treatment publication-title: Nat. Rev. Neurol. doi: 10.1038/nrneurol.2014.100 – volume: 35 start-page: 141 year: 2018 ident: 10.1038/s41374-021-00667-6_bib82 article-title: Impact of PCR-based molecular analysis in daily diagnosis for the patient with gliomas publication-title: Brain Tumor Pathol. doi: 10.1007/s10014-018-0322-3 – volume: 129 start-page: 585 year: 2015 ident: 10.1038/s41374-021-00667-6_bib32 article-title: IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas publication-title: Acta Neuropathol. doi: 10.1007/s00401-015-1398-z – ident: 10.1038/s41374-021-00667-6_bib7 – volume: 114 start-page: 97 year: 2007 ident: 10.1038/s41374-021-00667-6_bib14 article-title: The 2007 WHO classification of tumours of the central nervous system publication-title: Acta Neuropathol. doi: 10.1007/s00401-007-0243-4 – volume: 321 start-page: 1807 year: 2008 ident: 10.1038/s41374-021-00667-6_bib25 article-title: An integrated genomic analysis of human glioblastoma multiforme publication-title: Science doi: 10.1126/science.1164382 – volume: 20 start-page: 1393 year: 2018 ident: 10.1038/s41374-021-00667-6_bib96 article-title: The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study publication-title: Neuro Oncol. doi: 10.1093/neuonc/noy048 – ident: 10.1038/s41374-021-00667-6_bib11 – volume: 5 start-page: 39 year: 2017 ident: 10.1038/s41374-021-00667-6_bib41 article-title: Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery publication-title: Acta Neuropathol. Commun. doi: 10.1186/s40478-017-0443-7 – volume: 20 start-page: 608 year: 2018 ident: 10.1038/s41374-021-00667-6_bib74 article-title: Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications publication-title: Neuro Oncol. doi: 10.1093/neuonc/nox183 – volume: 372 start-page: 2499 year: 2015 ident: 10.1038/s41374-021-00667-6_bib30 article-title: Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1407279 – volume: 7 start-page: 59 year: 2019 ident: 10.1038/s41374-021-00667-6_bib38 article-title: DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development publication-title: Acta Neuropathol. Commun. doi: 10.1186/s40478-019-0704-8 – volume: 80 start-page: 431 year: 2021 ident: 10.1038/s41374-021-00667-6_bib54 article-title: Molecular characterization of “True” low-grade IDH-wild-type astrocytomas publication-title: J. Neuropathol. Exp. Neurol. doi: 10.1093/jnen/nlab023 – volume: 37 start-page: 136 year: 2020 ident: 10.1038/s41374-021-00667-6_bib76 article-title: Glioblastomas harboring gene fusions detected by next-generation sequencing publication-title: Brain Tumor Pathol. doi: 10.1007/s10014-020-00377-9 – volume: 133 start-page: 1 year: 2017 ident: 10.1038/s41374-021-00667-6_bib23 article-title: Announcing cIMPACT-NOW: the consortium to inform molecular and practical approaches to CNS tumor taxonomy publication-title: Acta Neuropathol. doi: 10.1007/s00401-016-1646-x – volume: 31 start-page: e12929 year: 2021 ident: 10.1038/s41374-021-00667-6_bib90 article-title: Prognostic relevance of adding MRI data to WHO 2016 and cIMPACT-NOW updates for diffuse astrocytic tumors in adults. Working toward the extended use of MRI data in integrated glioma diagnosis publication-title: Brain Pathol. doi: 10.1111/bpa.12929 – volume: 35 start-page: 106 year: 2018 ident: 10.1038/s41374-021-00667-6_bib101 article-title: Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion publication-title: Brain Tumor Pathol. doi: 10.1007/s10014-018-0312-5 – volume: 131 start-page: 234 year: 2007 ident: 10.1038/s41374-021-00667-6_bib16 article-title: New immunohistochemical markers in the evaluation of central nervous system tumors: a review of 7 selected adult and pediatric brain tumors publication-title: Arch. Pathol. Lab. Med. doi: 10.5858/2007-131-234-NIMITE – volume: 22 start-page: 936 year: 2020 ident: 10.1038/s41374-021-00667-6_bib97 article-title: “Real world” use of a highly reliable imaging sign: “T2-FLAIR mismatch” for identification of IDH mutant astrocytomas publication-title: Neuro Oncol. doi: 10.1093/neuonc/noaa041 – volume: 30 start-page: 541 year: 2019 ident: 10.1038/s41374-021-00667-6_bib35 article-title: IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations publication-title: Brain Pathol. doi: 10.1111/bpa.12801 – volume: 23 start-page: 565 year: 2013 ident: 10.1038/s41374-021-00667-6_bib47 article-title: PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma publication-title: Brain Pathol. doi: 10.1111/bpa.12043 – volume: 34 start-page: 1326 year: 2013 ident: 10.1038/s41374-021-00667-6_bib94 article-title: Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis? publication-title: Am. J. Neuroradiol. doi: 10.3174/ajnr.A3352 – volume: 74 start-page: 442 year: 2015 ident: 10.1038/s41374-021-00667-6_bib43 article-title: CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas publication-title: J. Neuropathol. Exp. Neurol. doi: 10.1097/NEN.0000000000000188 – volume: 62 start-page: 2152 year: 1988 ident: 10.1038/s41374-021-00667-6_bib13 article-title: Grading of astrocytomas. A simple and reproducible method publication-title: Cancer doi: 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T – volume: 16 start-page: 3851 year: 1998 ident: 10.1038/s41374-021-00667-6_bib70 article-title: DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma publication-title: J. Clin. Oncol. doi: 10.1200/JCO.1998.16.12.3851 – volume: 138 start-page: 331 year: 2019 ident: 10.1038/s41374-021-00667-6_bib100 article-title: Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas publication-title: Acta Neuropathol. doi: 10.1007/s00401-019-02025-9 – volume: 136 start-page: 153 year: 2018 ident: 10.1038/s41374-021-00667-6_bib44 article-title: Novel, improved grading system(s) for IDH-mutant astrocytic gliomas publication-title: Acta Neuropathol. doi: 10.1007/s00401-018-1849-4 – volume: 22 start-page: 515 year: 2020 ident: 10.1038/s41374-021-00667-6_bib50 article-title: Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria publication-title: Neuro Oncol. doi: 10.1093/neuonc/noz200 – volume: 131 start-page: 803 year: 2016 ident: 10.1038/s41374-021-00667-6_bib26 article-title: The 2016 World Health Organization classification of tumors of the central nervous system: a summary publication-title: Acta Neuropathol. doi: 10.1007/s00401-016-1545-1 – volume: 2 start-page: 24 year: 2018 ident: 10.1038/s41374-021-00667-6_bib61 article-title: Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways publication-title: NPJ Precis. Oncol. doi: 10.1038/s41698-018-0067-9 – volume: 20 start-page: 66 year: 2018 ident: 10.1038/s41374-021-00667-6_bib46 article-title: Prognostic relevance of genetic alterations in diffuse lower-grade gliomas publication-title: Neuro Oncol. doi: 10.1093/neuonc/nox132 – volume: 136 start-page: 181 year: 2018 ident: 10.1038/s41374-021-00667-6_bib53 article-title: Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience publication-title: Acta Neuropathol. doi: 10.1007/s00401-018-1879-y – volume: 38 start-page: 1 year: 2021 ident: 10.1038/s41374-021-00667-6_bib66 article-title: The molecular framework of pediatric-type diffuse gliomas: shifting toward the revision of the WHO classification of tumors of the central nervous system publication-title: Brain Tumor Pathol. doi: 10.1007/s10014-020-00392-w – volume: 34 start-page: 141 year: 2017 ident: 10.1038/s41374-021-00667-6_bib18 article-title: Modified rapid immunohistochemical staining for intraoperative diagnosis of malignant brain tumors publication-title: Brain Tumor Pathol. doi: 10.1007/s10014-017-0293-9 – volume: 37 start-page: 33 year: 2020 ident: 10.1038/s41374-021-00667-6_bib4 article-title: Correlation between IDH, ATRX, and TERT promoter mutations in glioma publication-title: Brain Tumor Pathol. doi: 10.1007/s10014-020-00360-4 – volume: 36 start-page: 56 year: 2019 ident: 10.1038/s41374-021-00667-6_bib86 article-title: Practical procedures for the integrated diagnosis of astrocytic and oligodendroglial tumors publication-title: Brain Tumor Pathol. doi: 10.1007/s10014-019-00337-y – volume: 6 start-page: 43 year: 2011 ident: 10.1038/s41374-021-00667-6_bib17 article-title: Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIalpha in human anaplastic astrocytomas–an immunohistochemical study publication-title: Diagn. Pathol. doi: 10.1186/1746-1596-6-43 – volume: 35 start-page: 148 year: 2018 ident: 10.1038/s41374-021-00667-6_bib88 article-title: Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas publication-title: Brain Tumor Pathol. doi: 10.1007/s10014-018-0321-4 – volume: 23 start-page: 865 year: 2021 ident: 10.1038/s41374-021-00667-6_bib56 article-title: TERT promoter mutation: is it enough to call a WHO grade II astrocytoma IDH wild-type glioblastoma? publication-title: Neuro Oncol. doi: 10.1093/neuonc/noab052 – volume: 142 start-page: 323 year: 2021 ident: 10.1038/s41374-021-00667-6_bib57 article-title: TERT promoter mutation status is necessary and sufficient to diagnose IDH-wild-type diffuse astrocytic glioma with molecular features of glioblastoma publication-title: Acta Neuropathol. doi: 10.1007/s00401-021-02337-9 – ident: 10.1038/s41374-021-00667-6_bib1 – volume: 36 start-page: 74 year: 2019 ident: 10.1038/s41374-021-00667-6_bib65 article-title: Molecular genetics and therapeutic targets of pediatric low-grade gliomas publication-title: Brain Tumor Pathol. doi: 10.1007/s10014-019-00340-3 – volume: 60 start-page: 248 year: 2001 ident: 10.1038/s41374-021-00667-6_bib59 article-title: Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading publication-title: J. Neuropathol. Exp. Neurol. doi: 10.1093/jnen/60.3.248 |
| SSID | ssj0014465 |
| Score | 2.6453834 |
| SecondaryResourceType | review_article |
| Snippet | The grading of gliomas based on histological features has been a subject of debate for several decades. A consensus has not yet been reached because of... |
| SourceID | proquest pubmed crossref springer elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 126 |
| SubjectTerms | 13/51 14/32 38/39 38/43 45/23 631/67/1922 692/499 Adult Amplification Astrocytoma Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism Brain cancer Brain Neoplasms - genetics Brain Neoplasms - metabolism Brain Neoplasms - pathology Central nervous system Chromosome 10 Chromosome 7 Chromosomes Classification Criteria Epidermal growth factor receptors Gene deletion Genetic markers Glioblastoma Glioma Glioma - genetics Glioma - metabolism Glioma - pathology Humans Isocitrate Dehydrogenase - genetics Isocitrate Dehydrogenase - metabolism Laboratory Medicine Markers Medicine Medicine & Public Health Mutants Mutation Neoplasm Grading Nervous system Oligodendroglioma Pathology Pediatrics Promoter Regions, Genetic - genetics Review Article Risk Telomerase - genetics Telomerase - metabolism Tumor Suppressor Protein p53 - genetics Tumor Suppressor Protein p53 - metabolism Tumors World Health Organization X-linked Nuclear Protein - genetics X-linked Nuclear Protein - metabolism |
| Title | Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System |
| URI | https://dx.doi.org/10.1038/s41374-021-00667-6 https://link.springer.com/article/10.1038/s41374-021-00667-6 https://www.ncbi.nlm.nih.gov/pubmed/34504304 https://www.proquest.com/docview/2622095630 https://www.proquest.com/docview/2571924435 https://www.proquest.com/docview/2775952160 |
| Volume | 102 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fb9MwED7BJiFe0DZ-rLBNRuINrLm24yRPE4xtBURBaBN9s5zYQUij2Zr2_-fOcbqHaX2p0sSJHJ99953vyx3AO-3HhXFB8CC84tqohruGQoh4HuXvlQqR5Ts1kyv9dZbN0oZbl2iVg06Mitq3Ne2RH0sjJSXNU-Lk5pZT1SiKrqYSGo9he4xIhEo35LO1wxWTgfUUD8UNemLpoxmhiuMOlXeuOREUIs-Tm4cM033geS9oGm3R-Q48SyCSfeylvguPwnwPnnxPYfLncHuxiNR41jYsJthgVAdl1QX25_ovEYKYq8nrpCbLliEGZBL7yH5PfrBYJZP4Q1Fk9ITL1b920dERNUzbwWyKSqZddaxPef4Crs7PLk8nPNVW4HUm8yWvnNfGiNwH1yBkUmiigsmq3JfGC-WFN6EpFaIVJxECOER1aPmlDo3MhcOhUy9ha97Owz4w9FBKj0DSBN_oom6cqdAr8hIlXYqqLEYwHgbW1inxONW_uLYxAK4K2wvD4ovaKAxrRvB-fc9Nn3ZjY-tskJdNwKEHBBbtwsb7Dgbh2rR0O3s30Ubwdn0ZFx1FUtw84NBa1HPkuCLU3NAmz7MSwZHB57zqJ876VZSmxHFCj-DDMJPuOvBwf19v7u8beCrp44zIKT-AreViFQ4RMi2ro7gu8Lc4HR_B9qez6c9f-O_zl2__Af7UD34 |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwEB6VIgGXqvwvFDASnMCq13ac5FAhBJQtbZfLVuzNOLGDkMqm3eyq4qV4RmacZHuourfeosSxbM945hvPeAbgjfbDzLggeBBecW1UxV1FLkR8j_T3SoUY5Ts2oxP9bZpMN-BffxeGwip7mRgFta9LOiPflUZKSpqnxIezc05Vo8i72pfQaNniMPy9QJOt2Tv4jPR9K-X-l8mnEe-qCvAykemCF85rY0Tqg6sQLCgUzsEkRepz44XywptQ5Qr1tJOo_BziGdR5UodKpsINVaqw31twW5OLEfdPOl0ZeDH5WBtSorhBy6-7pCNUttugskg1p4CIGFfKzXWK8CrQveKkjbpvfxu2OtDKPrZcdh82wuwB3Dnu3PIP4fzrPIbis7piMaEHo7oryyawX6e_KQCJuZKsXGqyqBliTiZxjOzH6DuLVTkpXimyCPUwWf6p5w09UcPu-JmNUajVy4a1KdYfwcmNrPpj2JzVs_AUGFpEuUfgaoKvdFZWzhRohXmJnJWLIs8GMOwX1pZdonOqt3Fqo8NdZbYlhsWJ2kgMawbwbvXPWZvmY23rpKeX7YBKC0As6qG1_-30xLWdqGjsJWMP4PXqM25y8ty4WcCltShXyVBGaLumTZomOYIxg_08aRlnNRWlKVGd0AN433PS5QCuH--z9eN9BXdHk-Mje3QwPnwO9yRdDInx7DuwuZgvwwuEa4viZdwjDH7e9Kb8D8egRzs |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3fb9MwED6NTZp4QfymY4CR4AmsunbiJA8TArbSMSgT2sTejFM7aNJotqYV4l_kr-LOcbqHaX3bW5U6keM7332X-3wH8Cpxg1xbL7gXTvFEq4rbilKIeB3l75TygeU71qPj5PNJerIG_7qzMESr7GxiMNSuntA38r7UUlLRPCX6VaRFHO4O351fcOogRZnWrp2GjW0W3E4oNxYPeRz4v38wnGt29ndR9q-lHO4dfRzx2HGAT1KZzXlpXaK1yJy3FQIJhYbb67TMXKGdUE447atCoQ-3Eh2jRayD_lAmvpKZsAOVKXzuLdjI0OtjILjxYW98-H2Z06DSZC3hRHGNcWE8wiNU3m_QlWQJJ7pEYJ1yfZ2bvAqDr6Rwg2cc3oU7EdKy960O3oM1P70Pm19j0v4BXHyaBaI-qysWyn0w6sqyaDz7dXZK9CRGazkLQ-Y1Q0TKJM6R_Rh9Y6FnJ7GZggLRE44Wv-tZQ79oYPw4zcZo8upFw9oC7A_h-EbW_RGsT-upfwIM46XCIazV3lVJPqmsLjFGcxL1rhBlkfdg0C2smcQy6NSN48yEdLzKTSsMgy9qgjCM7sGb5T3nbRGQlaPTTl4mwpgWnhj0Uivv2-6Ea6Ihacyl2vfg5fJvNAGU17FTj0tr0OpSGI3Ad8WYLEsLhGoan_O4VZzlq6iEytiJpAdvO026nMD1891aPd8XsIkb1HzZHx88hduSTo0Esvs2rM9nC_8Msdy8fB43CYOfN70v_wMRGFIW |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Grading+of+adult+diffuse+gliomas+according+to+the+2021+WHO+Classification+of+Tumors+of+the+Central+Nervous+System&rft.jtitle=Laboratory+investigation&rft.au=Komori%2C+Takashi&rft.date=2022-02-01&rft.issn=1530-0307&rft.eissn=1530-0307&rft.volume=102&rft.issue=2&rft.spage=126&rft_id=info:doi/10.1038%2Fs41374-021-00667-6&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0023-6837&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0023-6837&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0023-6837&client=summon |